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Exfoliation syndrome (EXS) also called pseudoexfoliation, was first described 
by the Finnish ophthalmologist J.G.Lindberg in 1917 as small white spots at the 
papillary border and on the lens capsule, depigmentation of the papillary border 
and translucency of the iris in cataractous, glaucomatous and normal elderly 
persons (Lindberg 1917). EXS is an age-related condition with generalised dis-
order of the extracellular matrix (ECM) characterized by a pathological accu-
mulation of polymorphic fibrillar extracellular material in the anterior segment 
of the eye (Schlötzer-Schrehardt & Nauman 2006) 
Exfoliative material (EXM) appears to be attached to various intraocular tis-
sues such as the lens epithelium, nonpigmented ciliary epithelium, trabecular 
epithelium, corneal endothelium, vascular endothelial cells and almost all cell 
types of the iris (Ritch & Schlötzer-Schrehardt 2001) 
EXM has also been identified in various tissues of the body, primarily in the 
connective tissue portion of the visceral organs (Schlötzer-Schrehardt & Nau-
man 2006) as well as the walls of the short posterior ciliary arteries and vortex 
veins (Schlötzer-Schrehardt 1991). 
Elevated intraocular pressure (IOP) has been reported in eyes with EXS 
(Arnarsson 2007, 2009; Mitchell et al. 1999; Kozart 1982). 
Patients with EXS are twice as likely to convert from ocular hypertension to 
glaucoma (Leske EMGT 2003) and are more likely to develop glaucoma at all 
IOPs (Topouzis 2009). 
Patients with exfoliative, also known as capsular, glaucoma (EXG) have a 
greater mean IOP, greater diurnal IOP fluctuation (Konstas et al. 1997), more 
visual field loss and optic disc damage at diagnosis, poorer response to medica-
tion, and greater need for surgical intervention, more rapid progression and a 
greater proportion of blindness (Ritch 2008).  
It has been suggested that increased lens opacification is associated with 
EXS (Hirvelä 1995; Hietanen 1992). However, it has been difficult to evaluate 
the direct risk factor for cataract formation, in terms of whether it is high IOP, 
glaucoma, glaucoma treatment or exfoliative process itself.  
EXS is known to be a major risk factor in modern extracapsular cataract sur-
gery and phacoemulsification. The risk of intraoperative problems, such as a 
poorly dilating pupil, zonular rupture, capsular break, and vitreous loss and 
postoperative complications including fibrinoid reaction, posterior synechias, 
cell deposits, and capsule contraction, is higher in eyes with the syndrome that 
have extracapsular cataract extraction (Skuta et al. 1987; Zetterström et al. 1992; 
Guzek et al. 1997) or phacoemulsification (Dosso et al. 1997; Hayashi et al. 
1998; Scorolli et al. 1998; Shastri & Vasavada 2001). 
Other ocular manifestations include dry eye (Kozobolis 1999), lens (and arti-
ficial intraocular lens) sub-luxation (Hayashi 1998; Breyer 1999), angle closure 
and retinal vein occlusion (Ritch 2010). 
Specular and electron microscopic studies have revealed both quantitative 
and qualitative corneal endothelial cell changes in eyes with EXS. EXS eyes 
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have been found to have a lower endothelial cell density than in non-EXS eyes. 
Changes in the percentage of hexagonal cells and the coefficient of variation of 
cell size have been shown when compared to eyes without EXS (Naumann & 
Schlötzer-Schrehardt 2000; Inoue et al. 2003; Wali et al. 2009). The characteris-
tic tissue alterations predispose to corneal endothelial decompensations which 
make them vulnerable during intraocular surgery, especially in cataract phacoe-
mulsification.  
This clinical study was designed to examine the prevalence of EXS in Esto-
nia and among patients scheduled for cataract surgery. The vulnerability of the 
corneal endothelium during cataract phakoemulsification in patients with or 





2. REVIEW OF THE LITERATURE 
2.1. Epidemiology 
Although the syndrome has since been discovered throughout the world, there is 
great variation in the prevalence of EXS in different regions and ethnic groups 
(Forsius 1988, Karger 2003, Arvind 2003) 
These variations may be a true genetic difference related to ethnicity or may 
be related to examination techniques, diagnostic abilities and criteria, selections 
of patient subgroups and patient age (Ritch & Schloetzer-Schrehardt 2001). 
 
 
2.1.1 Prevalence of exfoliation syndrome 
Since EXS has been discovered, it has mainly been evaluated as a Scandinavian 
syndrome. Though the detected occurrence of EXS is worldwide, reported 
prevalence rates of exfoliation syndrome vary widely in different geographic 
locations, from 0% of Inuits (Forsius 1979) and 0.9% in Australia (McCarty 
2000), 1.7 % in Congo (Kaimbo 2012) and 3.4% in Japan (Miyazaki 2005), 
5.5% in France (Colin 1988) and 6.0% in Southern India (Krishnadas 2003), 
9.6% in Iran (Nouri-Mahdavi 1999) and 9% in Lithuania (Spečkauskas 2012), 
10.7% in Iceland (Arnarsson 2009) and 11.9% in Creece (Anastasopoulos et al. 
2011) up to 25.3% in northern Finland (Forsius 1979) and 38% for Navajo 
Indians (Faulkner 1972). Very low (0.4%) prevalence rates have been reported 
among the Chinese population (Young 2004). The prevalence of EXS differs 
remarkably even in different regions and altitudes of one population (Kozobolis 
1997, 1999). It also has been suggested that persons living in lower latitudes 
appear to develop EXS at younger age (Ringvold 1996). 
Some years ago Dr. Taylor, on the basis of his study results, debated whether 
EXS is an environmental disease (Taylor 1979). Interesting data comes from 
Stein and colleagues, who assessed the risk of EXS by geographic latitude tier. 
Compared with middle-tier residence, northern-tier residence (above 42°N) was 
associated with an increased hazard of EXS while southern-tier (below 37°N) 
was associated with a reduced hazard on EXS. For each additional sunny day 
annually, the hazard increased by 1.5% in a location with an average level of 
other climatic factors (Stein 2011). Contrary to those findings, Forsius & 
Luukka found no EXS in Innuit versus in 20% of Lapps lining at the same lati-
tude (Forsius & Luukka 1973). Kang et al. demonstrated that people of Nordic 
extraction in the United States were not at increased risk for EXS, (Kang 2012). 
The lack of clear association with other climate-related disorders of ocular con-
nective tissue (Forsius 2002) suggests that we are dealing with a very different 
cause for EXS, in which climate might play only a consequential role. 
The distribution of EXS between two genders is found to be variable as well. 
Some studies have shown EXS to be significantly more prevalent in men 
(Taylor 1980, Yalaz 1992, Kozobolis 1997, Nouri-Mahdavi 1999) and some 
find it more prevalent in women (Hiller 1982, Ekström 2008, Åström 2007 I, 
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Arnarsson 2009), while other studies show no gender difference (Stefanitou 
1990; McCarty & Taylor 2000, Arvind 2003, Miyazaki 2005, Jeng 2007, Qui-
roga 2010). 
EXS is an age-dependent disorder in most of studies, the prevalence of EXS 
increases with age (Karger 2003, Miyazaky 2005, Krause 1988, Åström 2007 II, 
Arnarsson 2009, Quiroga 2010, Kanthan 2013,) and is seldom found before the 
age of 50 (Tarkkanen 1962, Forsius 2002). In population studies, patients with 
EXS have found to be significantly older than those without it (Arnarsson 2007, 
Arvind 2003, Miyazaki 2005). In a study conducted by Karger and colleagues 
(Karger 2003) the age-adjusted annual incidence of EXS was 25.9 per 100,000 
and it was higher among females than males (32.7 vs 16.9).  
 
 
2.1.2. Prevalence of glaucoma in subjects with exfoliation syndrome 
EXS has been suspected as an independent and strong risk factor for glaucoma. 
Elevated IOP with or without glaucomatous damage occurs in approximately 
25% of subjects with EXS or about 6–10 times the rate in eyes without EXS 
(Ritch 2001). In a review, Forsius (1988) found the prevalence of glaucoma in 
EXS to vary around the world considerably, from 0% in the United States to 
83% in Argentina. He found roughly one half of EXS eyes have glaucoma. In 
the Thessaloniki Eye Study, the proportion with glaucoma among subjects with 
EXS was higher than that for glaucoma among non-EXS participants, 15.2% 
versus 4.7% respectively (Anastasopoulos 2011). A study by Jeng et al. (2007) 
found 16% of EXS patients to have glaucoma at the time of diagnosis and that 
the risk of EXS conversion to EXG is about 60%. Karger et al. (2003) con-
cluded their study with a similar result, 16% of EXS patients had glaucoma and 
28% of EXS subjects developed EXG during a 16-year follow-up time. The 
Blue Mountains Eye Study confirmed the strong relationship between glaucoma 
and EXS. Subjects with EXS had an increased risk of glaucoma, which was 
independent of other glaucoma risk factors, including IOP (Mitchell 1999). In 
another study from Australia McCarty with colleagues found that positive pre-
dictive values for glaucoma were 22% in EXS-positives and 12% in EXS-nega-
tives (McCarty 2000). The glaucoma conversion rate has been found to be twice 
as high in patients with ocular hypertensive (OHT) and EXS as a conversion of 
OHT without EXS (Grødum et al. 2005). 
 
 
2.1.3. Prevalence of exfoliation syndrome in patients with glaucoma 
Ritch in his review postulate that the prevalence of EXS in glaucoma cohorts is 
significantly higher than in age-matched non-glaucomatous populations (Ritch 
2001). Most population studies report a higher prevalence of EXS among pri-
mary open-angle glaucoma (POAG) patients (Arnarsson 2007; Mitchell 1999; 
Topouzis 2007). The prevalence of EXS among patients with POAG has been 
reported to vary from 1.4% in the USA (Ball 1988) to 50% in Finland (Hirvelä 
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1995) and 60% in Norway (Ringvold 1991). In a Finnish population, Hirvelä 
found one-third of newly diagnosed glaucomas were exfoliative (Hirvelä 1995). 
In a review, Forsius (1988) found the prevalence of EXS in Finland of patients 
with glaucoma to be from 24% to 66%. In the study by Åström et al. (2007) 
59% of glaucoma patients also had EXS at the age of 87 years. In the Blue 
Mountains Eye Study, a strong and significant relationship was found between 
EXS and glaucoma (Mitchell 1999). Glaucomatous damage was present in 
14.2% of eyes with EXS compared to 1.7% of eyes without EXS. The age- and 
gender-adjusted odds ratio was 5.0 (95% CI 2.6–9.6) and this remain unchanged 
(OR 4.8) after adjustment to glaucoma risk factors and was also relatively unaf-
fected by IOP adjustment (OR 3.7; 95% CI 1.8–7.6,) (Mitchell 1999). Arnars-
son and colleagues in the Reykjavik Eye Study found those with EXS to have a 
four-fold likelihood of having glaucoma compared to those without EXS 




In different studies (Damji 1998; Allingham et al. 2001; Thorleifsson et al. 
2007) a genetic component in EXS is suggested. Interesting results from Fors-
man et al. propose that EXS is consistent with an autsomal dominant trait with 
incomplete penetrance, where the penetrance is more reduced in males than in 
females (Forsman 2007). In a milestone study by Thorleifsson et al. two risk 
variants in the lysyl oxidase-like 1 (LOXL1) gene were identified as being 
strongly associated with EXS (Thorleifsson 2007). The LOXL1 in one of the 
enzymes is essential for the formation and maintenance of elastin fibres (Jonas-
son 2007). LOXL1 protein is a major component of exfoliation deposits and ap-
pears to play a role in its accumulation and in concomitant elastotic processes in 
intra- and extra-ocular tissues of EXS-patients (Ritch 2008, Schlötzer-Schre-
hardt 2009). 
The currently proposed pathogenesis of EXS is a oxidative stress-related, 
excessive production by elastogenic cells of elastic microfibrils that aggregate 
into a typical configuration through an enzymatic cross-linking process (Schlöt-
zer-Schrehardt & Naumann 2006). 
 
 
2.1.5. Exfoliative material 
In EXS, the EXM accumulates throughout the anterior segment. There is more 
than one theory for EXM formation. It has been proposed that the EXM is for-
med by focally detached corneal endothelial cells with hypertrophized secretory 
organelles. An abnormal extracellular matrix is synthesized, composed of base-
ment membrane material, microfibrils and EXM fibres. Descemet’s membrane 
appears to be thickened with irregular excrescences and diffuse melanin deposi-
tion (Schlötzer-Schrehardt 1993; Naumann & Schlötzer-Schrehardt 2000). Those 
changes can lead to early corneal endothelial decompensation. Electron- micro-
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scopy has shown large aggregates of typical EXM adhering to the corneal endo-
thelium (Naumann & Schlötzer-Schrehardt 2000). 
According to another hypothesis, mechanical friction between the iris and 
the lens, which could lead to micro-fibrillar material being rubbed off of the 
surface of the anterior lens capsule, where EXM was produced (Ritch 1994). 
EXM fibrils observed in surface of the corneal endothelial cells may originally 
come from the lens surface (Prince & Ritch 1986). The friction between the 
fragile papillary margin of the iris and the lens may cause increased pigment 
dispersion in EXS eyes (Prince & Ritch 1986) and spreaded melanin granules 
are then phagocytised by endothelial cells (Naumann & Schlötzer-Schrehardt 
2000). A proportion of the subsequently accumulated fibrillar eosinopilic mate-
rial sticks to the corneal endothelium because of its adhering capabilities 
(Ringvold 1994). This accumulation of EXM and melanin granules may lead to 
corneal endothelial decompensation (Naumann & Schlötzer-Schrehardt 2000). 
At a moment, there is no consensus regarding the location of production and 
delivery of EXM. 
Streeten et al. (Streeten 1986) first described the elastic microfibril theory of 
pathogenesis, based on similarities between EXM and zonular fibers, and ex-
plained EXS as a type of elastosis affecting elastic microfibrils. This fibrogran-
ular material is composed of microfibrillar subunits and is surrounded by an 
amorphous matrix comprising various glycoconjugates (Streeten 1986; Morri-
son & Green 1988). Exfoliation fibrils have a characteristic ultramicroscopic 
appearance of 20–30 nm thickness, with 10 nm subunits and may be 800 to 900 
nm long (Seland 1988). Those crossbanded fibrils and filamentous subunits 
contain predominantly epitopes of elastic fibers such as elastin, tropoelastin, 
laminin, amyloid P, vitronectin and components of elastic microfibrils (Ovo-
denko 2007).  
Growing evidence implicates oxidative stress and inflammation in EXS 
pathogenesis. The EXS-specific tissue alterations are caused by a generalised 
fibrotic matrix process, which has been characterized as a stress-induced elasto-
sis associated with the excessive production and abnormal cross-linking of 
elastic microfibrils into fibrillar EXM aggregates, (Schlötzer-Schrehardt 2011). 
Eagle et al. (1979) were the first to detect EXM outside the eye globe, in the 
walls of the short posterior ciliary arteries adjacent to the basement membrane 
of the smooth muscle cells. Exfoliation-like fibres have been detected in skin-
biopsy specimens (Streeten 1990) in various peribulbar tissues such as extraoc-
ular muscles, walls of wortex veins, orbital connective tissue septa and the optic 
nerve sheaths of EXS-patients (Schlötzer-Schrehardt 1991). Interestingly, EXM 
was also found in the clinically unaffected fellow eyes (Schlötzer-Schrehardt 
1991). In many studies EXM in autopsy tissue specimens obtained from skin, 
heart, lungs, liver, kidney and cerebral meninges was revealed in patients with 
intraocular EXS (Schlötzer-Schrehardt 1992; Streeten et al 1992). According to 





2.2. Clinical picture of exfoliation syndrome  
2.2.1. Features of exfoliation syndrome 
Exfoliation syndrome is characterized by the development of white, dundruff-
like flakes throughout the anterior ocular segments. Exfoliative material is de-
posited in various tissues: the posterior corneal surface, the pupillary border, the 
anterior chamber angle, the lens zonules and ciliary processes. EXM on the lens 
surface appears as a central disc and peripheral band with a biomicroscopically 
clear intermediate zone (Lindberg 1917, Layden 1974, Schlötzer-Schrehardt 
1993). 
Pigment dispersion from the iris is known to appear first, before EXM can 
be detected by biomicroscopy. These clinical signs include the liberation of pig-
ment into the anterior chamber after pupillary dilatation, loss of pigment at the 
pupillary margin, transillumination of the iris and pigment deposition on the 
anterior lens capsule, corneal endothelium, iris surface, and the trabecular mesh-
work (Layden 1974; Prince & Ritch 1986; Schlötzer-Schrehardt 1993).  
A pigmentation of the trabecular meshwork is found to be the predominant 
feature of the EXS (Krause 1973; Layden 1974). A particularly suggestive fin-
ding may be pigmentation of the upper portion of the anterior chamber angle 
or/and specific pigmentation of the irido-corneal angle, known as Sampaolesi’s 
line (Sampaolesi et al. 1988) 
 
 
2.2.1.1. Vascular changes in exfoliaton syndrome 
Vascular changes are pronounced in the eyes with EXS. A fluorescein angi-
ography of the limbal vasculature reveals loss of the regular vascular pattern in 
the limbus and areas of neovascularisation in advanced cases, as well as con-
gestion of the anterior ciliary vessels (Laatikainen 1971, Raitta & Vannas 
1971). Those abnormalities of the iris vessels, loss of radial vessels and ob-
struction of vessels are shown to cause tissue hypoxia and hypoperfusion that 
result in neovascularisation of the iris tissue and leakage of fluorescein due to 
impairment of the blood-aqueous barrier (Vannas 1969; Ringvold & Davanger 
1981; Cambiaggi 1988). Ritch et al. found in their prospective study that central 
retinal vein occlusion is commonly associated with EXS (Ritch 2010). Reduced 
ocular and cerebral blood flow has been reported by several authors (Harju & 
Vesti 2001; Yüksel 2001). 
 
 
2.2.1.2. Corneal endothelium in exfoliation syndrome 
It has been suggested that corneal endothelium metabolism is unsettled in eyes 
with EXS induced a loss of endothelium cells. These endothelial cell changes 
are induced by altered composition and increased flare intensity of the aqueous 




In normotensive patients with unilateral EXS Puska with colleagues did not 
find quantitative or qualitative morphological changes or differences in corneal 
endothelium between the two eyes. The endothelial cell density (ECD) was, on 
an average, 3.6 +11.4% lower in the EXS-eyes but the difference was not sig-
nificant. They also did not find EXM on the corneal endothelium in any eye 
(Puska 2000). 
On the other hand, Romero-Aroca in his population-based study found that 
changes such as lower endothelial cell density and low hexagonality percentage 
with higher coefficient of variation are common findings in patients with EXS, 
especially in older age groups, and may predispose patients to increased cell 
loss during cataract surgery, (Romero-Aroca 2011). This study found that com-
plications in cataract surgery were higher in patients with EXS and postopera-
tive corneal oedema was best correlated with a low hexagonality percentage 
(Romero-Aroca 2011). Among normotensive and nonglaucomatous patients sche-
duled for cataract surgery, Quiroga and colleagues found a larger percentage of 
patients (21.3% vs 9.3%), with ECD lower than 2000 cells/mm2, in patients 
with EXS compared to non-EXS, (Quiroga 2010). 
Changes in corneal endothelium have also been more prevalent in normoten-
sive patients, with EXS than in without EXS. Those changes, such as the 
polymegethism and pleomorphism of corneal endothelial cells, have been dis-
covered in both eyes of patients with unilateral EXS and these changes were 
essentially the same overtly affected and apparently normal fellow eyes (Wir-
belauer 1998). After comparing normotensive EXS eyes to normal eyes without 
EXS and to eyes with no ocular disease other than senile cataract, in their study, 
Miyake and colleagues suggested that the corneal endothelial changes are con-
sistent in eyes with EXS and can be considered as an early sign of the disorder, 
(Miyake 1989).  
Also, Inoue found significantly lower corneal endothelial density in EXS 
eyes compared to non-EXS eyes, and there was no difference between glauco-
matous or non-glaucomatous eyes (Inoue 2003).  
On the other hand, Østern and Drolsum, in their prospective study among 
patients with and without EXS who underwent cataract surgery, found no sig-
nificant difference in ECD in two groups before the surgery or after 6–7 years 
of follow-up. No significant differences in polymegathism or pleomorphism 
were asserted. Investigators found no reduction in ECD according to glaucoma 
status. Also, no clinical signs of corneal decompensation were noted amongst 
the participants (Østern and Drolsum 2012). 
Wali and colleagues concluded that in glaucomatous eyes with EXS ker-
atopathy endothelial cell polymegethism and pleomorphism is more frequently 
associated with male gender than with cataract. Interestingly, the correlation of 
pleomorphism and polymegathism was stronger for patients <60 years (R(2) = 
0.7268, p = 0.01) than >60 years old (R(2) = 0.5805, p = 0.01,) (Wali 2009).  
There is also study (Gagnon 1997) in which patients with POAG were com-
pared to those without glaucoma; ECD were found to be significantly lower in 
patients with glaucoma. Patients receiving three or four topical glaucoma medi-
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cations had lower cell counts than those receiving one or two medications 
(Gagnon 1997). Gagnon and colleagues concluded that in glaucoma patients 
proposed harmful mechanisms could be direct damage from raised IOP, con-
genital alteration of the corneal endothelium, toxicity of topical medication or a 
combination of all of these, (Gagnon 1997). 
In patients with advanced EXS, a distinct type of corneal endotheliopathy 
may occur, which can lead to a corneal endothelial decompensation. In a study 
on patients with clinically diagnosed EXS and irreversible corneal decompen-
sation by Naumann & Schlötzer-Schrehardt, histological material was obtained 
from patients undergoing penetrating keratoplasty. Histopathologically corneal 
buttons showed an abnormal diffuse, irregular thickening of Descemet’s mem-
brane and focal accumulations of locally produced EXM. Also, clinically the 
patients showed diffuse corneal oedema, a pleomorphic and numerically re-
duced corneal endothelium, and retrocorneal flakes of EXM in some cases 
(Naumann & Schlötzer-Schrehardt 2000). Investigations, conducted by the 
same study group in electronic microscopy revealed large clumps of typical 
EXM that were adhered to the corneal endothelium and masses of EXM were 




2.2.1.3. Corneal thickness in exfoliation syndrome 
Some studies have found that nonglaucomatous and glaucomatous subjects with 
EXS have thicker corneas compared to those without EXS (Puska 2000; 
Stefaniotou 1992). Stefaniotou found that subjects with EXS had significantly 
thicker corneas compared to subjects without EXS, but corneal thickness sho-
wed no significant difference between EXS and normal fellow eyes (Stefanio-
tou 1992). In their study in normotensive eyes with early EXS Puska et al. 
found higher values of central corneal thickness (CCT) in the exfoliative eyes 
compared to fellow nonexfoliative eyes (Puska 2000). On the contrarily, Inoue 
and colleagues found significantly thinner central corneas in patients with EXS 
compared to non-EXS patients and there was no difference whether affected eye 
were glaucomatous or not (Inoue 2003). Also Özcura and colleagues found that 
mean CCT is significantly thinner in nonglaucomatous EXS eyes compared to 
nonEXS eyes (Özcura 2011). In a large population (N = 1045), in a patients 
with or without glaucoma, the Reykjavik Eye Study, did not find a significant 
difference of CCT between subjects with or without EXS, and the result was 
also the same after adjusting for the effects of age and gender (Arnarsson et al. 
2007). In his study Cankaya did not find any significant differences in CCT 
between normal eyes and EXS eyes with or without glaucoma (Cankaya 2012). 
Østern and Drolsum had similar results in their study among patients with and 





2.2.2. Clinical course of exfoliation syndrome 
While the classic picture of manifest EXS has been written about detail, the 
early stages of the beginning of EXS have not been well defined. Development 
of the syndrome from the first pigmentary changes to the full-scale exfoliation 
syndrome picture is supposed to take 5–10 years (Jerndal 1985).  
 
 
2.2.2.1. Monocular or binocular involvement 
EXS is shown to be a bilateral process, which often has clinically unilateral in-
volvement.  
In a study by Romero-Aroca et al. the unilateral prevalence of EXS was 
70.9% (Romero-Aroca 2011). Klemetti found that clinically EXS often occurs 
unilaterally but in up to 41% of cases it may develop in the fellow eye (Klemetti 
1988). In a study conducted by Puska (Puska 2002) in 10 year follow-ups 38% 
had converted to bilateral. No risk factors for conversion to bilateral EXS were 
found. Åstöm and colleagues found in the group of subjects with unilateral EXS 
that 55% converted to bilateral EXS during a 21-year follow-up period (Åstöm 
et al. II 2007). Andrikopoulos and colleagues indicated similar results; bilateral 
EXS is more frequent than unilateral with the percentage of bilateral EXS rising 
with progressing age (Andrikopoulos 2009). Unilateral EXS occurs at a younger 
age than bilateral (Tarkkanen 1962; Klemetti 1988). However, there is a retro-
spective study, which found a cumulative incidence of conversion to bilateral 
EXS to be 0.11 at 5 years, 0.36 at 10 years and 0.52 at 15 years (Tarkkanen 
2004).  
The question has arisen of whether the EXS is histologically a bilateral dis-
order with asymmetric clinical onset. EXM has been ultrastructurally identified 
in contralateral eyes that are clinically free of exfoliation (Schlötzer-Schrehardt 
1991, Konstas 1993, Prince 1987, Ritch 2010). 
 
 
2.2.2.2. Ocular hypertension and glaucoma in exfoliation syndrome 
The vast majority of studies have found IOP being higher in EXS than in non-
EXS eyes (Arvind 2003, Mitchell 1999, Arnarsson 2007, Kozart 1982, Damji 
1999), with a few exceptions (McCarty 2000, Krishnadas 2003). The IOP ele-
vation seen in EXS is more likely caused by EXM detaching from the cells that 
produce it and then floating in anterior segment until it attaches itself in the 
trabecular meshwork, thereby creating an increased resistance of aqueous hu-
mour (Schlötzer-Schrehardt 2006). 
The elevation of IOP is well known risk factor for glaucoma. But not all 
EXS affected eyes develop ocular hypertension or glaucoma: 65.5% of the EXS 
eyes remained normotensive in study of Klemetti (1988) with follow-up time of 
1–23 years. Similar results were detailed in study by Thornburn (1988) in which 
the presence of EXS in a healthy eye seemed to have no prognostic value for the 
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development of glaucoma. The essential changes that affect ocular tension are 
thought to take place in the early phase of the exfoliative process (Hansen & 
Sellevold 1970) and the risk of developing glaucoma is considered to be highest 
relatively shortly after the development of fibrillopathy (Aasved 1971)  
An Early Manifest Glaucoma Trial study found that in patients with early 
glaucoma, IOP remained stable without treatment during a 6-year period, re-
gardless of baseline IOP, except for patients with EXG, where IOP increased by 
almost 1 mmHg annually (Hyman 2010). The Thessaloniki Eye Study produced 
interesting findings where for screening IOP < 20 mmHg the proportion with 
glaucoma was similar in subjects with and without EXS. For IOP level > 20 
mmHg the proportion with glaucoma increased significantly in subjects both 
with and without EXS, while it was much higher among those with EXS at the 
same screening IOP (Topouzis 2009). Similar to the prevalence of EXS, the 
incidence of EXG seems to be an age-dependent disease. Topouzis and collea-
gues in their study did not find any EXG patient in the group 60 to 64 year age-
group, while it was 1% in the 65 to 69 age-group and 2.5% in 80 years and 
older age-group (Topouzis 2007). This increase in the prevalence of EXG with 
increasing age was statistically significant. In the Thessaloniki Eye Study, IOP 
was a significant risk factor associated with both, EXG and POAG (Topouzis 
2011). Patients with EXG and POAG have been found to have significantly 
lower values of CCTcompared with normal subjects of the same age (Alpenza-
Dunato 2011), which gives a lower IOP value in Goldmann tonometry. Similar 
results were reported in several other studies; CCT was significantly thinner in 
patients with EXG (Gorezis 2008; Özcura 2011) and significantly thicker in 
cases of ocular hypertension (Gorezis 2008). 
Some studies have indicated that the effect of EXS on ocular pathology is 
more complicated than solely through pressure increase caused by decreased 
outflow. Puska et al (Puska 1999) in their 3-year prospective study found that in 
normotensive patients, with unilateral EXS and equal IOP of both eyes through-
out the study, the changes in the optic disk were only found in the eye with EXS 
suggesting the present of a deteriorating factor other than elevated IOP. How-
ever, the relationship between glaucomatous damage and IOP seems to be 
stronger in EXG than in POAG, and EXS has been identified as a major risk 
factor for open-angle glaucoma (Naumann 1998). Furthermore, EXG is charac-
terised with rapid progression, more resistant to medical treatment and worse 
prognosis than POAG (Teus MA 1998, Leske et al 2003, Schlötzer-Schrehardt 
& Naumann 2006, Jonasson 2007). 
 
 
2.3. Exfoliation syndrome and lens opacification  
Although the nature of the relationship is not well understood, increasing evi-
dence has been presented for an association between EXS and cataract for-
mation (Taylor 1979; Hiller 1982; Puska 1994). Objective quantification of lens 
changes has been a problem due to methodological and instrumental limitations. 
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In the majority of studies, especially earlier studies, objective methods were not 
used to measure lens opacity. Raitta & Vesti (1991) and Vesti (1993) used Lens 
Opacity Meter and found that, at corresponding ages, opacity units were higher 
in eyes with EXG than in eyes with POAG. Also in a study by Puska & 
Tarkkanen (2001), the development of lens opacities was followed using the 
Lens Opacity Meter. At the beginning of the study, the mean lens opacity was 
23.5 opacity units (OU) in EXS eyes and 22.9 OU in, initially non-EXS, fellow 
eyes with no significant difference. After five years, the mean opacity was 30.0 
OU and 26.9 OU in EXS and non-EXS fellow eyes, respectively, with a signifi-
cant difference. In patients who remained unilaterally affected, the EXS eye had 
a higher opacity value compared to non-EXS eyes at the start of the study and 
after a five-year follow-up (Puska & Tarkkanen 2001). Hirvelä at al. in a popu-
lation-based study found that EXS was present in one or both eyes in 22% of 
the patients with cataract and EXS was found to be a significant risk factor for 
cataract (Hirvelä 1995). We do have evidence that EXS is a risk factor for lens 
opacification. Increased lens opacification is suggested to be associated with the 
EXS in many studies (Layden & Schaffer 1974; Vesti 1993; Puska & 
Tarkkanen 2001; Romero-Aroca 2011), but these two phenomena have also 
been linked by age factor. 
 Due to population ageing in Western countries, there is an increased preva-
lence of EXS in eyes coming to cataract surgery and an increased prevalence of 
cataracts in eyes with EXS.  
 
 
2.3.1. Lens opacification in exfoliation syndrome 
The lens depends on the aqueous for its metabolism. In the EXS changes in the 
composition of the aqueous can intervene to lens metabolism and cause lens 
opacification. The exact role of high IOPs as a cause of lens opacification in not 
known, but there is evidence that association between increased IOP and lens 
opacification do exist (Klein 1997). Also patients on the IOP-lowering treat-
ment have singnificantly greater risk to have nuclear opacities (Leske 2002; 
Heijl 2002). 
There is theory that cataract formation is related to ocular ischemia and that 
the virtually constant association we have noted clinically between unilateral 
cataract and asymmetric EXS, the two occurring in the same eye, is indicative 
of greater ischemia in the involved eye (Ritch & Schlötzer-Schrehardt 2001). 




2.3.2. Exfoliation syndrome and subtype of cataract 
In clinical and histopathologic studies, the predominant type of cataract in EXS 
is shown to be a nuclear sclerosis.  
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In a clinical study of patients scheduled for cataract surgery, Hietanen found 
that nuclear cataract is a predominant type of cataract in eyes with EXS as com-
pared with patients without EXS, 83% vs 62%, while the frequency of cortical 
cataract was the same, 15% vs 17%, and that of posterior subcapsular cataract 
was lower, 2% vs. 22% (Hietanen et al. 1992). 
The Reykjavik Eye Study found that EXS was linked to nuclear lens opacifi-
cation (Arnarsson 2009). Similar results were found in a study by Sekeroglu et 
al. in which, the most common type of cataract was nuclear in the EXS-group 
(33.5%) and 24.6% of patients with mature cataract had EXS (Sekeroglu 2008). 
Identical findings have been reported in studies worldwide, (Obuchowska 2006, 
Teshome 2004, Benatiya 2006). 
In a histopathologic study of intacapsularly removed lenses, anterior cortical 
(12% vs. 30%), equatorial cortical (49% vs. 65%), posterior (10% vs. 25%) and 
supranuclear (40% vs. 60%) cataract were found to be less common in EXS 
than in non-EXS eyes. Nuclear cataract was more prevalent (88% vs. 82%) in 
EXS eyes. Posterior subcapsular cataract (55% vs. 55%) showed no difference 
while the anterior subcapsular was slightly less common in non-EXS eyes, 
(12% vs. 17%,) (Seland & Chylack 1982). 
 
 
2.3.3. Exfoliation syndrome and cataract surgery 
EXS has also been linked to ocular pathologies such as zonular and capsular 
weakness, poor pupillary dilatation, blood-aqueous barrier breakdown, retinal 
vein occlusion and corneal endothelium decompensation. These concomitant symp-
toms can lead to increased risk of surgical complications seen in these patients 
(Scorolli et al. 1998; Schlötzer-Schrehardt & Naumann 2006, Shingleton 2010).  
It has been presupposed that in EXS eyes might be at a higher risk of decline in 
corneal endothelial cell density after cataract surgery. 
Corneal endothelial cell loss is a well-known, undesirable side-effect of cata-
ract surgery that can, in severe cases, negatively impact patients’ postoperative 
visual outcomes.  
Lundberg and colleagues found the central corneal swelling at postoperative 
day 1 was strongly correlated with the central corneal cell loss at 3 months R = 
0.785, p<0,001 (Lundberg 2005). Complications in cataract surgery are higher 
in patients with EXS, and postoperative corneal oedema was correlated with a 
low hexagonality percentage (Romero-Aroca 2011). Nevertheless, there is an 
interesting study where after 6–7 years following cataract surgery no significant 
differences were established in endothelial cell density, pleomorphism, poly-
megethism and corneal thickness in eyes with or without EXS, with no clinical 





2.4. Exfoliation syndrome and systemic diseases  
Studies suggest that EXS is not exclusively an ocular condition but rather a 
systemic-one. EXS material has been identified in different tissues of the body, 
primarily in a connective tissue of visceral organs (Schlötzer-Schrehardt & 
Naumann 2006). EXM has been found in various organs of a body such as in 
the heart, lung, liver, kidney and gall-bladder and also in meninges of patients 
with ocular EXS (Schlötzer-Schrehardt & Naumann 2006; Streeten 1992). EXS 
has been associated with transient ischemic attacks, arterial hypertension and 
myocardial infarction (Repo 1995; Mitchell 1997). EXS has also reported to be 
a risk factor for coronary artery disease (Andrikopoulos 2009; Citirik 2007; 
Sekeroglu 2008). Djordjevic-Jocic with colleagues revealed significantly higher 
frequency of abdominal aortic aneurysm in patients with EXS and EXG than in 
patients with POAG or cataract (Djordjevic-Jocic et al. 2012). On other hand, 
Romero-Aroca et al. (2011) and Anastasopoulos et al. (2011) found no connec-
tion between EXS appearance and systemic diseases. Åstöm at al. (2007) did 
not find significant difference in mortality between individuals with or without 
EXS. In the Thessaloniki Eye Study, Topouzis and colleagues found that vascu-
lar diseases and their treatment were associated only with POAG (Topouzis 
2011). Tarkkanen et al. (2008), using the Finnish Social Insurance Institution 
registry, found no difference in the frequency of arterial hypertension or ische-
mic heart disease in patients with EXG or POAG. This study also reported a 
significantly lower prevalence of diabetes mellitus in EXS-patients compared to 
POAG (Tarkkanen et al. 2008). Allingham et al. 2001, nevertheless, found no 
association between EXS and cardio- and cerebro-vascular disease, arterial hy-
pertension or diabetes mellitus. Similarly to last mentioned study, Spečkauskas 
in his population-based study found no association between EXS and ischaemic 
heart disease, arterial hypertension and diabetes mellitus (Spečkauskas 2012). 
Although EXS has been associated with a more systemic pathological con-




3. AIMS OF THE RESEARCH 
1. To determine the prevalence of EXS in Estonia. To examine differences in 
related ophthalmological variables, such as IOP and glaucoma, in subjects 
with EXS and without EXS. To estimate the prevalence of EXS in patients 
scheduled for cataract surgery.  
2. To assess the EXS as a possible risk factor for lens opacification. 
3. To compare the influence of various cataract surgery pre-, intra- and post-
operative characteristics to corneal endothelium and thickness in patients 





4. DEFINITIONS, SUBJECTS AND METHODS 
4.1. Definitions  
EXFOLIATION SYNDROME 
Exfoliation syndrome was defined as occurrence of biomicroscopically detecta-
ble typical white-greyish material on the anterior surface of the lens, and/or at 
the pupil margin (Puska 2001). Findings of few pigmentary granules on the 
anterior lens surface, on the iris and on the corneal endothelium without exfoli-
ative material were not defined as EXS. 
 
GLAUCOMA was defined as IOP > 21 mmHg with typical glaucomatous chan-
ges of the optic disc with or without visual field defects found on the visual 
field evaluation with Humphrey perimeter. Optic nerve heads were considered 
glaucomatous on biomicroscopical examination with the Volk lens in the pres-
ence of focal or generalized narrowing or disappearance of the neuroretinal rim 
with an enlarged amount of cupping or pallor (Park 1996).  
 
OCULAR HYPERTENSION was defined as IOP > 21mmHg without optic 
nerve head changes or visual field defects (Puska 2002).  
 
MATURE CATARACT was defined as a totally opacified lens, either brunes-




This thesis is based on the results of three clinical studies. The studies were per-
formed in accordance with ethical standards laid down in the Declaration of 
Helsinki and informed consent was obtained from all participants. The studies 
were approved by the Ethics Committee of the University of Tartu.  
The studies were conducted in the Eye Clinic of the Tartu University Clinics. 
All subjects and patients were examined by same investigator, Dr. Kuldar Kalju-
rand. All patients were operated on by one surgeon, Prof. Pait Teesalu. 
 
 
4.2.1. Prevalence of exfoliation syndrome in Estonia (I) 
A cross-section, population-based study was conducted to determine the preva-
lence EXS in Estonia. Seven hundred and sixty-six residents, chosen by random 
sampling from the Estonian Population Database from the city of Tartu, Esto-
nia, were invited to participate in this study. 424 subjects (55.4%) of all samples 
did participate. All participants were aged fifty years or older and of Finno-
Ugric origin. The cohort was divided into decades (50–59; 60–69; 70–80; 81–). 
All patients underwent a slit-lamp examination before and after pupil dilatation 
and a thorough ophthalmologic examination. Visual fields were tested with 
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Humphrey perimeter. Cases with definite or suspicious pathologic findings 
were directed for further evaluation. The epidemiological data were collected 
based on an interview with the patient including history of the eye diseases or 
surgery, family history for glaucoma, history and duration of systemic disease 
and use of ocular or/and systemic medications. 
 
 
4.2.2. Exfoliation syndrome in Estonian patients  
scheduled for cataract surgery (II) 
This prospective study comprised 305 consecutive patients (105 male, 200 fe-
male) aged 40–93 years (mean 71.5 +8.6) scheduled for cataract surgery, phaco-
emulsification with intraocular lens implantation, in the Eye Clinic of Tartu 
University Clinics. The age group of 70–79 years constitutes 48.8% of all pa-
tients. Slit-lamp estimation was performed before and 30–40 minutes after the 
dilatation of the pupils. Pupil size was measured before and after dilatation. The 
slit-lamp examination was used to look for localisation of the exfoliation mate-
rial. In pseudophakic and aphakic fellow eyes, exfoliation material was sought 
for in the other locations except the lens. The predominant type of lens opacity 




4.2.3. Exfoliation syndrome as a risk factor for corneal  
endothelial cell loss in cataract surgery (III) 
In the prospective study 37 consecutive patients (18 male, 19 female) aged 51–
85 years (mean 73.5) scheduled for cataract surgery with EXS and 37 patients 
(16 male, 20 female) aged 43–84 years (mean 68.1) without EXS as a control 
group underwent a preoperative ophthalmologic examination. The axial length 
(AL), anterior chamber depth (ACD) and lens thickness were measured and 
keratometry together with specular microscopy was performed. The intraope-
rative factors and volume of balanced salt solution (BSS) were recorded. Pre-
vious ocular surgery, ocular trauma, high myopia, history of uveitis and abnor-
malities of the cornea were exclusion criteria for the study. Patients with mature 
cataract were not included in the study. Postoperative dexamethazone with 
chloramphenicol (Oftan DexaChlora, Santen) drops were used 5 times daily for 
3 weeks, and thereafter 3 times daily for 2 weeks. None of the patients were 










Table 1. Summary of study subjects and patients 









75.5 (+ 8.6) 
37 EXS; 37 nonEXS 
73.5 EXS (+8.3); 
68.1 nonEXS (+8.0) 
  
Measured 









IOP: pre-,  
postdilatation 
Pupil: pre-,  
postdilatation 








Type of cataract 









sis of corneal endo-
thelial cells 
 
Mydriasis 1% cyclopentolate + 
10% phenylephrine 
hydrochloride 
1% cyclopentolate +  
10% phenylephrine 
hydrochloride 






4.3.1. Clinical ophthalmological examination 
Pupil size was measured before and after dilatation with a special ruler under 
the same lighting conditions. The presence of EXS was confirmed 30–40 minu-
tes after mydriasis with 1% cyclopentolate and 10% phenylephedrine as typical 
exfoliative material deposits either on the anterior lens surface, on the pupillary 
border or on the corneal endothelium and pigment on the anterior lens capsule 
was recorded. Intraocular pressure was measured before and after dilatation by 
using the Goldmann applanation tonometer. Visual acuity (VA) was estimated 
before dilatation using Landolt’s acuity charts with lens correction achieving 
the best VA. The lens was evaluated through dilated pupil using slit-lamp bio-
microscopy. The type of cataract (if presented) was recorded as nuclear, corti-
cal, sub- capsular or mixed. Mature cataract was defined as a totally opacified 
cataract, either brunescent or white, and was included in the mixed type of 
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cataract. Stereoscopic examination of the vitreous, retina and optic nerve was 
made at the slit lamp after dilatation with a 90D (Volk) lens. The axial length, 
anterior chamber depth and lens thickness were measured preoperatively by 
ultrasonography Humphrey A/B scan system 837, (Humphrey Instruments Inc., 
San Leandro, California, USA). Preoperative keratometry was performed using 
a OAP211 keratometer (Carl Zeiss OAP 211, Carl Zeiss, Jena, Germany).  
All patients underwent Humphrey automated perimeter (Humphrey Field 
Analyzer II HFA 750i/GPA, Carl Zeiss Meditec Inc., Dublin, CA USA). The 
presence of glaucoma, ocular hypertension or other ocular disease and previous 
intraocular surgery or trauma was registered.  
 
 
4.3.2. Phacoemulsification  
All patients scheduled for cataract surgery underwent phacoemulsification 
(phaco) without complications through a self-sealing limbal tunnel incision.  
All operations were made using the same phaco equipment, Protegé, Storz 
Ophtahlmics (Storz Protégé Microsurgical Systems, Storz instrument com-
pany, St.Louis, Mo, U.S.A.), by one experienced surgeon (PT), who was blin-
ded regarding the study participants. Topical anesthesia with 2% oxubrucaine 
eye drops (Alcain, Alcon) and the temporal approach was used in all cases. 
After circular continuous capsulorhexis (CCC), phacoemulsification inside the 
capsular bag was performed. Following initial groove formation into the nuc-
leus, the chopping technique was used. Before CCC and intraocular lens (IOL) 
implantation, the viscoelastic substance (Celoftal®, Alcon) was injected into the 
eye. The wound was enlarged up to 5 mm before the implantation of IOL 
(Bausch&Lomb, model EZE-50). At the end of the operation, the viscoelastic 
was removed from the anterior chamber as well as from behind the IOL. Eva-
luated intraoperative factors were overall operation time, elapsed phaco time, 
phaco power, overall phaco impact (phaco time multiplied with phaco power) 
and volume of balanced salt solution (BSS; Bausch&Lomb).  
 
 
4.3.3. Examination of the corneal endothelial cells  
Corneal endothelial cells were photographed and corneal thickness was meas-
ured using automatic noncontact specular microscope (Specular Microscope 
SP-2000P, TOPCON Instrument Corp, made in Japan, Tokyo). This device 
provides rapid morphometric analysis and has reliable reproducibility (Bovelle 
1999; Modis 2002). ECD, average cell area and coefficient of variation (CV; 
Standard Deviation / average cell size x 100) were recorded in the centre of the 
cornea and in four paracentral, (superior, inferior, temporal and nasal quadrants) 
locations. Examinations were made sequentially in a central and fixed paracen-
tral area to analyze regional differences. The positions were placed on the 6 mm 
diameter circle, each position 3 mm from the centre of the cornea. To determine 
the endothelial cell density, the endothelial cells were counted in a rectangular 
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frame placed manually with constant (0.1 x 0.1 mm) area. The frame adjacent 
cells were marked manually with a mouse and digitized. Only high-contrast and 
focused endothelial images with sufficient quality and resolutions were noted. 
Examinations were made preoperatively, on the first postoperative day and 4 
weeks after surgery. The 4 week follow-up period was considered to be suffi-
cient because exposure of corneal endothelial cell damage is already detectable 
in the first postoperative month (Walkow 2000; Wirbelauer 1998; Milla 2005; 




4.3.4. Statistical analysis 
All data was analyzed using the SAS software package (release 6.12, SAS In-
stitute Inc.). Age and IOP were used as continuous variables. Statistics were 
performed using the Student t test and the Mann-Whitney U test was used to 
compare differences between the eyes. Pearson’s chi-square 2-sided test was 
used to test the frequencies of lens opacities in the paired eyes. Analyses by 
subjects were also performed with logistic regression. The 95% confidence 
intervals of the prevalence were estimated and p< 0.05 was selected to denote 





5. RESULTS  
5.1. Prevalence of exfoliation syndrome in  
Estonian population (I) 
This cross-section population-based study consisted of 424 subjects in which 
277 (65.3%) were female and 147 (34.7%) were male. The median age of par-
ticipants was 70 years (range 50–98 years), in males 71 years (range 51–98 
years) and in females 70 years (range 50–93 years). The median age of subjects 
of EXS was 72 years (range 51–93). Subjects in the EXS group were older than 
in the non-EXS group but the difference was not statistically significant.  
 
 
5.1.1. Prevalence of exfoliation syndrome 
The overall prevalence of EXS among the study participants in one or both eyes 
was 25.5% (108); 25.2% (37/147) in male and 25.6% (71/277) in female pa-
tients, p = 0.9. The bilateral involvement of EXS was detected in 36 (33.3%) of 
all EXS cases, and there was no significant difference in appearance of EXS 
between the two eyes in both genders (p = 0.91, 95% CI 0.7–1.4). The preva-
lence of EXS increases by age (Table 2). 
 
 
Table 2. Regression analyses of prevalence of EXS, by age 
EXS Odds ratio Std. err. p [95% CI] 
50–59 1.0 (Ref.)    
60–69 3.32 1.58  0.012 1.30–8.44 
70–79 5.23 2.40 <0.001 2.12–12.89 
80– 5.02 2.51  0.001 1.88–13.41 
EXS = Exfoliation syndrome 
Std. Err. = Standard error 
95% CI = 95% confidence interval  
Ref = Reference group 
 
 
5.1.2. Exfoliation syndrome and intraocular pressure  










Table 3. IOP before and after pupil dilatation 
 IOP (mmHg) 
[95%] CI 
 











mmHg = millimetre of Mercury  
IOP = intraocular pressure 
non-EXS = without exfoliation syndrome 
EXS = exfoliation syndrome. 
 
 
5.1.3. Prevalence of glaucoma 
Glaucoma was found in 70 (16.5%) participants with no difference in appear-
ance between both genders (p = 0.6). Glaucoma was significantly more frequent 
in the EXS group than the non-EXS group, 35.7% vs. 11.3%, respectively  
(p <0.05). In logistic regression analysis the prevalence of glaucoma was not 
age-dependent in our study (Table 4). 
 
 
Table 4. Regression analyses of prevalence of glaucoma, by age and gender 
Glaucoma Odds ratio Std. err. p [95% CI] 
50–59 1.0 (Ref.)    
60–69 0.99 0.42 0.9 0.42–2.31 
70–79 2.07 0.80 0.06 0.96–44.4 
80– 0.54 0.33 0.33 0.16–1.84 
Female 1.0 (Ref.)    
Male 0.63 0.19 0.14 0.35–1.15 
Std. Err = Standard error 
95% CI = 95% confidence interval 
Ref = Reference group 
 
 
5.1.4. Prevalence of cataract 
Any type of lens opsification in one or both eyes was found in 41.5% of male 
and 40.8% female participants with no statistically significant differences be-
tween two eyes and genders. The prevalence of the cataract was detected in 
57.0% of cases in the EXS-group compared to 39.5% in the non-EXS group  
(p = 0.002). Nuclear cataract was more often represented in the EXS-group but 
was not statistically significant (p = 0.14). Patients with cataract were signifi-
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cantly older compared to patients without it and the median age was 74 and 70 
years, respectively (p<0,001). In logistic regression analysis, adjusted to age, 
subjects with EXS have 1.5-fold risk of having cataract compared to the non-
EXS group (p = 0.003); both age and EXS have a significant influence on cata-
ract formation (Table 5). 
 
 
Table 5. Regression analyses of formation of cataract, by EXS and age 
Cataract Odds ratio Std. err. p [95% CI] 
EXS 2.03 0.48 <0.01  1.28–3.21 
 
Cataract Odds ratio Std. err. p [95% CI] 
EXS 1.56 0.41  0.09  0.96–2.63 
50–59 1.0 (Ref.)    
60–69 2.86 1.23  0.01  1.23–6.64 
70–79 11.46 4.75 <0.01  5.08–25.85 
80– 29.70 15.37 <0.01 10.78–81.90 
Std. Err = Standard error 
EXS = Exfoliation syndrome 
95% CI = 95% confidence intervall 
 
 
There were no differences in pupil diameter between two groups before dilata-
tion. Mydriasis was lesser in the non-EXS group but statistically not signifi-
cantly. 
Similar prevalence of systemic diseases was found in both groups of both 
genders. 
There was no difference between the two groups in visual acuity (p = 0.9). 
 
 
5.2. Exfoliation syndrome in Estonian patients  
scheduled for cataract surgery (II) 
In the whole study group (n = 305, 105 male and 200 female; mean age 71.5 
+8.6 years. EXS was detected in 35.4% of patients scheduled for cataract sur-
gery with 47.2% bilateral and 52.8% unilateral involvement.  
In the affected eyes, EXM was noted on the anterior lens capsule of 96.7% 







Table 6. Disposition of EXM on the lens anterior capsule 
 Central disc Perferal band Pupillary border Posterior cor-
neal surface 
EXM 53 (59.6%) 81 (91.0%) 69 (75.0%) 8 (8.7%) 
EXM = exfoliation material 
 
 
EXM was noted only after pupil dilatation in the peripheral part of the lens an-
terior capsule in 15% of the patients.  
Pigment granules were found on the anterior lens surface and posterior cor-
neal surface of 33.7% operative eyes. Only 9.0% of operative eyes without EXS 
had pigment dusting on the anterior lens capsule and corneal endothelium. 
 
 
5.2.1. Pre- and postoperative intraocular pressure 
In eyes scheduled for cataract surgery, IOP was higher in eyes with EXS than in 
those without EXS (19.2 + 6.5 vs. 17.1 + 3.8 mmHg, p = 0.006), and they re-
mained at a higher level after dilatation (18.6 + 7.3 vs. 16.4 + 4.1 mmHg,  
p = 0.013).  
Ocular hypertension was found in 31 (10.2%) operative eyes of which 16 
(51.6%) had EXS and 15 (48.4%) were without EXS. 
 
 
5.2.2. Prevalence of glaucoma 
There was no difference in the mean IOP between patients with EXG or with 
POAG (20.6 vs. 21.0 mmHg, p = 0.507). EXG embraces 54.4% of all cases of 
glaucoma. 
Forty-five (14.8%) patients had glaucoma in the eye scheduled for cataract 
surgery; of these, 25 (8.2%) patients had glaucoma in both eyes.  
In bilaterally phakic eyes with unilateral EXS (n = 41) glaucoma was rec-
orded in 13 (31.7%) exfoliative and in 6 (14.6%) non-exfoliative eyes. 
 
 
5.2.3. Type of lens opacification in operative eye 
The operative eyes with EXS differed significantly from non-EXS in the pre-













non-EXS EXS p 
N % N % 
nuclear 78 36.8 53 57.6 <0.001 
 
cortical 36 17.0 7 7.6 
subcapsular 43 20.3 7 7.6 
mixed 55 25.9 25 27.2 
total 212 100.0 92 100.0 
Data is missing for one non-EXS patient.  
EXS = exfoliation syndrome 
non-EXS = without exfoliation syndrome 
 
 
Nuclear sclerosis was the predominant type of cataract (57.6%) in EXS eyes 
followed by other type of cataract. 
Mature cataract was found in 21 EXS and 12 non-EXS eyes (33 out of 80 
mixed cataracts; 41.3%).  
Mydriasis was significantly lesser in eyes with EXS (6.4 + 1.1 vs. 7.2 + 0.9 
mm, p < 0.0001). 
The eyes with EXS scheduled for cataract surgery did not differ from non-
EXS in visual acuity (p = 0.099). 
 
 
5.3. Exfoliation syndrome as a risk factor for corneal 
endothelial cell loss in cataract surgery (III) 
Thirty-seven consecutive patients with and 37 patients without EXS as a control 
group scheduled for cataract surgery were studied. Nineteen patients with post-
operative corneal oedema, eight from the EXS and 11 from the non-EXS group 
were not included into analysis because of difficulties in endothelial cell count-
ing on the first postoperative day. Two patients from the EXS group with an 
endocapsular ring placement were also not included because this surgical ma-
neuver might cause additional damage to endothelium. The mean patient age in 
the EXS group was significantly older than in non-EXS group, 73.5 (range 51–
85) years +8.3 (SD) and 68.1 (range 43–84) years +8.0 (SD,) (p = 0.02). 
Patients with EXS had less mydriasis but the difference was not significant 








Tabel 8. Pre- and postoperative variables.  
Variable EXS group non-EXS group p 
n = 27 26  
Age, years 73.5 (±8.3) 68.1 (±8.0) 0.02 
Sex, F:M 19:8 20:6  
Pupil, preop ø (mm) 3.6 (±0.6) 3.9 (±0.7) 0.1 
Pupil, postop ø (mm) 4.8 (±0.9) 5.0 (±0.9) 0.4 
IOP, postop, mmHg 17.6 (±4.5) 16.7 (±2.7) 0.4 
IOP, postop (24h) 24.8 (±11.7)  19.7 (±6.0) 0.07 
IOP, postop (1 month) 16.5 (±3.4) 17.3 (±5.4) 0.6 
ACD, mm 2.98 (±0.4) 2.98 (±0.4) 0.9 
Lens thickness, mm 4.4 (±0.6) 4.3 (±0.6) 0.7 
Axial length, mm 23.2 (±0.7) 23.4 (±1.2) 0.5 
Keratometry K1 43.5 (±1.6) 
K2 43.8 (±1.3) 
K1 43.3 (±1.2) 
K2 43.1 (±1.3) 
0.09 
mm = millimetre 
mmHg = millimetre of Mercury 
IOP = intraocular pressure  
ACD = anterior chamber depth 
 
 
5.3.1. Preoperative parameters of corneal endothelial cells 
Patients in the study and in the control group had similar anterior chamber 
depts, lens thicknesses, axial lengths and keratometry measured values as well 
as in pre- and postoperative pupil sizes. IOP was equal in both groups, but with 
a higher variability in the EXS group (Table 8). There was no significant differ-
ence in the pre- and postoperative visual acuity between two groups. 
The mean preoperative corneal ECD, average cell area, CV as well as thick-
ness of the cornea did not differ significantly between EXS and non-EXS 
groups (Table 9). The mean preoperative corneal central ECD was 2543 (417) 
in the EXS group and 2594 (519) in the non-EXS group, the mean paracentral 
ECD values were 2479 (±422) and 2455 (±475), respectively. Preoperative 
mean central ECD values were higher than paracentral (the average of superior, 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.3.2. First postoperative day 
There was a statistically significant difference in the paracentral but not the 
central endothelial cell loss in the first postoperative day between the EXS and 
non-EXS patients (Table 9). The decrease of the central ECD was 9.8%  
(p = 0.04) in the EXS and 9.5% (p = 0.05) in the non-EXS patients. The 
decrease of the paracentral ECD was 8.2% (p < 0.001) in the EXS and 1.1%  
(p = 0.4) in the non-EXS patients.  
The immediate postoperative (24h) increase of CV indicated a temporary 
heterogenity of endothelial cell size after the surgery that returned near to the 
baseline value during one month. The increase of CV occurred in the central 
and paracentral cornea in both group, but the difference between EXS and non-
EXS eyes was not significant. 
In the paracentral area, but not in the central area, the average cell area was 
significantly larger in the EXS patients than in the paratsentral area compared to 
non-EXS patients. 
On the first postoperative day the thickness of the central as well as para-
central cornea was significantly increased in both groups, indicating oedema, 
which returned to the baseline level during one month (Table 9).  
IOP was higher in the EXS group and it had higher variability, though not 
statistically significant (24.8 ±11.7 vs. 19.7 ±6.0 mmHg, p = 0.07,) (Table 8) 
 
 
5.3.3. One-month follow-up 
The decreases of the mean central and paracentral corneal ECD values in compari-
son with the preoperative values were 18.1% (p < 0.001) and 12.3% (p < 0.001) in 
the EXS group and 11.6% (p = 0.08) and 6.6% (p = 0.04) in the non-EXS 
group, respectively. The decrease of ECD was more pronounced in EXS group 
but the difference between the two groups was not statistically significant 
(Table 9).  
The average cell area was more increased (compensatory to endothelial cell 
loss) in the EXS group (99 μm2 centrally; 63 μm2 paracentrally) than in the 
non-EXS (45 μm2 centrally; 20 μm2 paracentrally) group one month postoper-
atively, but the difference did not reach statistical significance (Table 9).  
CV had recovered to the preoperative level after the one month follow-up. 
The postoperative significant increase of CV only sustained in the paracentral 
area in the EXS group, but the difference the two groups was not significant 
(Table 9). 
The thickness of the cornea of both groups had returned to the preoperative 
state one month after the operation (Table 9). In regression analysis we did not 
find a correlation between corneal thickness and ECD loss in any follow-up 
time point.  
After one-month follow-up IOP was on the preoperative level in both 
groups. In regression analysis, the pre- and postoperative (24h) IOP, as the main 
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effect, did not have an influence on central ECD (p = 0.9, p = 0.6 respectively;  
r2 = 0.47) 
 
 
5.3.4. Intraoperative parameters 
Operation time was similar in both groups. 
The consumption of BSS and phaco time showed significant differences be-
tween the groups; other operation parameters showed no statistically significant 
difference (Table 10). 
 
 
Table 10. Operation parameters 
Variable EXS group (±SD) non-EXS group (±SD) p 
Oper. time, min 12.4 (±4.3) 11.1 (±2.9) 0.2 
Phaco power, % 44.0 (±13.2) 41.0 (±16.0) 0.5 
Phaco time, sec 92    (±44) 71    (±32) 0.05 
Overall phaco impact 25.96 20.8 0.2 
BSS, mm 26.8 (±7.1) 19.8 (±7.5) 0.001   
EXS = patients with exfoliation  
nonEXS = patients without exfoliation 
SD = Standard Deviation 
BSS = balanced salt solution 
Overall phaco impact = phaco power multiplied with phaco time 
 
 
In regression analysis the consumption of BSS and phaco time did not have a 
statistically significant influence to ECD one month after surgery. Regression 
analysis revealed that phaco power had a significant negative impact to ECD 
(centrally r2 = 0.47, p = 0.02; paracentrally r2 = 0.39, p < 0.001). There was also 
a significant influence of overall phaco impact (phaco power multiplied with 
phaco time) to overall ECD (central, + 4 paracentral) decline (r2 = 0.30,  
p = 0.02). EXS as the main effect or in interaction with phaco power did not 
have an influence on endothelial cell loss (p = 0.2), but it had a significant in-
fluence on endothelial cell loss in interaction with overall phaco impact (r2 = 0.27, 
p = 0.05). 
A statistically significant negative association between the age of patients 
and the postoperative central as well as overall ECD one month after surgery 
was found in regression analysis (r2 = 0.47, p = 0.004 and r2 = 0.45, p = 0.004; 
respectively). The presence of EXS does not have an impact on ECD in interac-
tion with age (p = 0.7).  
There was also a statistically significant negative association in regression 
analysis between the preoperative ECD and the change in ECD, indicating that 
the larger the preoperative cell density, the larger the postoperative cell loss  
(r = 0.45, p < 0.001). EXS did not have an influence on postoperative ECD in 




Epidemiological studies are needed in every country in order to obtain evi-
dence-based data about every specific population. This data is important for 
planning medical and social care.  
In the prospective population-based gross-section study, we investigated the 
prevalence of EXS in Estonia. Additionally, we looked at the IOP-level of par-
ticipants, prevalence of glaucoma, lens opacity, and subtype of cataract. We 
evaluated the coexistence of EXS with systemic conditions. We also compared 
patients with EXS to those without EXS on different parameters.  
Secondly, we examined the prevalence of EXS in patients scheduled for cat-
aract surgery. This study addressed several clinical aspects such as frequency of 
EXS and glaucoma, pre- and postoperative IOP, mydriasis and the type of lens 
opacity in cataract patients.  
Thirdly, the potential clinical impact of EXS in cataract phacoemulsification 
to corneal morphology was investigated.  
 
 
6.1. Advantages and limitations 
The advantages of these studies include the random population sample, the rel-
atively high prevalence of EXS in this population and the prospective nature of 
these investigations. Our population-based study subjects were randomly cho-
sen from the Estonian Population Database. In the prevalence study of EXS in 
patients scheduled for cataract surgery and in a study of EXS as risk factor for 
corneal endothelium, all participants were consecutive patients, without any 
pre-selection.  
One deficiency of this investigation is that the information about systemic 
conditions was self-reported. Other limitations include the relatively low pro-
portion of the oldest age-group and the lack of opportunity to examine immo-
bile persons. Theoretically those persons could be more commonly affected; 
therefore, EXS may be somewhat underrepresented in this investigation. How-
ever, Krause et al. (1988), in their study conducted in elderly houses found a 
similar prevalence of EXS as aged matched non-institutionalized individuals.  
 
 
6.2. Prevalence of exfoliative syndrome  
in the Estonian population 
The reported prevalence of EXS in different populations varies extensively in 
the literature ((from 0% of Inuits (Forsius 1979), up to 22.4% in Finland 
(Krause 1988)). It is a well-known fact that EXS is common in Nordic coun-
tries. Worldwide prevalence varies greatly and it is difficult to distinguish dis-
tinct geographical distribution. The difference between many of these studies 
may be a true genetic difference related to ethnicity or may be related to exami-
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nation techniques, diagnostic abilities and criteria, use of mydriatics, sampling 
methods and age distribution (Ritch & Schloetzer-Schrehardt 2001).  
In our study of the Estonian population, the prevalence of EXS was 25.5% in 
subjects fifty years and older, which is the same as in Finland. Forsius in his 
two different studies on the prevalence of EXS in Finland found prevalence 
from 21% up to 25.3% in northern Finland (Forsius 1979; 1988). Forsman in 
her population-based study in the subisolate island of southern Finland found 
prevalence of EXS to be 8.1% in subjects over 50 years of age which increased 
to 18.4% for subjects over 70 years of age (Forsman 2007). The similar preva-
lence rates in our and in the Finnish studies are not surprising as both nations, 
Finland and Estonia, are of Finno-Ugric origin. Studies have revealed varying 
gender difference in prevalence of EXS. We did not find any difference in the 
gender distribution (25.6% in female and 25.2% in male, p = 0.9) of EXS, 
which is in accordance with many studies (Forsius 1988; Arvind 2003; McCarty 
2000; Miyazaki 2005; Krishnadas 2003). Some investigators have reported a 
male preponderance (Nouri-Mahdavi 1999; Forsman 2007; Kozobolis 1997) but 
some also reported female preponderance (Karger 2003; Mitchell 1999; Åström 
& Lindén 2007; Arnarsson 2007; Ekström & Alm 2008). Although EXS occurs 
worldwide the prevalence among different geographic and racial populations 
and even inside the same ethnic populations varies considerably. At the mo-
ment, to our knowledge, commonly accepted methodology and diagnostic crite-
ria for the definition of EXS do not exist. A lack of uniformly manageable epi-
demiologic studies does not facilitate estimating the true differences of preva-
lence of EXS and taking into consideration the influence of the possible impact 
of climate, socio-economic situation and cultural differences of different popu-
lations.  
Distribution of EXS for bilateral vs. unilateral cases is highly variable in re-
ported cases (Nouri-Mahdavi 1999; Kozobolis 1997; Kozart & Yanoff 1982) 
the percentage of bilateral involvement varies from ¼ to ¾. Most studies indi-
cate that EXS is basically a bilateral syndrome although the clinical presentation 
is often unilateral. In a prospective 10-year follow-up study, Puska (Puska 
2002) found that 38% of unilateral EXS cases had converted to bilateral. 
Arnarsson et al. had similar results in their study: 71% of clinically unilateral 
cases had converted to bilateral in 12 years (Arnarsson 2012). We found bilat-
eral involvement of EXS in 33.3% of cases in our study. There was no signifi-
cant difference in the appearance of EXS between the two eyes in both genders. 
In our study, subjects with the bilateral involvement of EXS, compared to uni-
lateral, were not significantly older, which is similar to other studies (Kozart & 
Yanoff 1982; Arvind 2003). 
As in many studies (Karger 2003; Arvind 2003; McCarty & Taylor 2000; 
Miyazaki 2005; Krause 1988; Kozobolis 1997; Mitchell 1999; Damji 1999; 
Åström 2007; Anastasopoulos 2011) if not in all, we found that the prevalence 
of EXS significantly increases with age. In the Thessaloniki Eye Study, in a 
large population (N = 2554), they found that participants with EXS were signifi-
cantly older than nonEXS participants, (mean age 73.8 vs 70.4 years, p < 0.0001) 
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(Anastasopoulos 2011). In our study the median age of the participants of EXS 
was higher than that of the non-EXS participants, but the difference was not 
significant. Age in our study profoundly increases the prevalence of EXS, but 
also substantially affects other ophthalmological variables and is therefore an 
important confounder to consider. 
In a review, Forsius reported the frequency of EXS in patients with cataract 
to vary from 0.3% in Poland, 3% in France, 9% in American Indians (New 
Mexico) up to 18% in Norway and 33% in Finland (Forsius 1988). EXS syn-
drome has been known to be associated with a greater prevalence of cataract, 
though the exact aetiology of this association is not known (Puska & Tarkkanen 
2001; Schlötzer-Schrehardt & Naumann 2006; Young 2004; Arvind 2003; 
Taylor 1979; Hiller 1982; Puska 1994; Puska & Tarkkanen 2001). Findings in 
our study are in strong agreement with the above-mentioned studies, as we 
found a significantly different prevalence of cataract was detected in 57% of 
cases in the EXS group compared to 39.5% in the non-EXS group (p = 0.002). 
Also, in agreement with these studies, we found patients with cataract to be 
significantly older than patients without it; the median age was 74 and 70 years 
respectively and the prevalence of cataract increased with age. Moreover, the 
regression analysis in our study showed that EXS adjusted for age had a signifi-
cant impact on cataract formation. Patients with EXS have a 1.5-fold age-ad-
justed risk of cataract. However there are studies were connections between 
EXS and cataract formation have not been found. Arnarsson and McCarthy in 
their population-based studies with large group of subjects did not find a sig-
nificant effect on the risk of cataract from EXS (Arnarsson 2009; McCarty 
2000).  
We found a tendency for nuclear cataract prevalence in the EXS group, 
which is similar to findings in earlier studies (Young 2004; Arvind 2003; Hieta-
nen 1992). Recently published data from The Blue Mountains Eye Study found 
significantly greater prevalence of nuclear cataract in eyes with EXS and this 
association persist after adjustment for age, gender, smoking, diabetes, steroid 
use, myopia, socioeconomic status and open-angle glaucoma, (Kanthan 2013). 
In the Reykjavik Eye Study nuclear cataract, like EXS, was also shown to be 
highly age-related but causally not related to EXS (Arnarson 2007). Moreover, 
in the same study, nuclear lens opacification in EXS patients compared to non-
EXS patients was highly significant until it was adjusted to age (Arnarson 
2007). On the other hand, Krishnadas and colleagues found that EXS was asso-
ciated with posterior subcapsular and cortical cataract, (Krishnadas 2003). The 
causative relationship between EXS and different types of cataract needs further 
clarification. 
In our population-based study, we found a significant relationship between 
IOP and EXS. IOP in our study was significantly higher in eyes with EXS com-
pared with the non-affected eye, before as well as after pupil dilatation. Simi-
larly, Ǻström & Lindén, in their population based study found that in partici-
pants with unilateral EXS IOP is significantly higher in the affected eye, but 
there was no difference between the mean IOP of the non-EXS eyes in subjects 
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with unilateral EXS and the IOP of eyes in those with no EXS in either eye 
(Ǻström & Lindén 2007). They also found that IOP > 22 mHg was in 17% of 
EXS eyes and 3.0% in the non-EXS eyes. One reason for the elevated IOP in 
EXS is the increased outflow resistance in the trabecular meshwork. There is 
evidence that decreased outflow is a result from a blockage of the outflow 
channels by EXM together with trabecular cell dysfunction, which may have 
causative relationship for glaucoma development and progression (Schlötzer-
Schrehardt U & Naumann 1995).  
In the Thessaloniki Eye Study subjects with EXS compared to those with no 
EXS had higher percentage of IOP > 22 mmHg. This finding was mainly ex-
plained by the higher proportion with glaucoma among EXS participants. In this 
study investigators concluded that patients with EXS, compared to non-EXS, 
had significantly higher mean IOP, but after excluding glaucoma patients the 
IOP was only 0.6 mmHg higher (p = 0.05) in EXS-positives (Anastasopoulos 
2011). However, there is a large population-based study from Australia (N = 5147), 
in which no significant relationship was found between IOP and EXS (McCarty 
& Taylor 2000). Similar conclusions were made by investigators in the Aravind 
Comprehensive Eye Survey study (Krishnadas 2003).  
According to existing evidence, the elevation of IOP is a well-known risk 
factor for glaucoma (Le et al. 2003; Heijl, EGTS 2002). In the Collaborative 
Initial Glaucoma Treatment Study (CIGTS) investigaros found the mean IOP at 
baseline significantly higher in the EXG patients compared to POAG patients 
(Musch 2012). In a study conducted by McCarty and colleagues strong relation-
ship between EXS and glaucoma was found after checking for age; although not 
highly sensitive, EXS was found to be a specific predictor of glaucoma status 
(McCarty & Taylor 2000). 
In earlier studies, the prevalence of glaucoma in eyes with EXS has been 
found to vary considerably, from 7% in the USA (Kozart & Yanoff 1982) to 
22.7% in Norway (Aasved 1971), 13.0% in the India (Arvind et al 2003) up to 
61% in Finland (Tarkkanen 1962). It has been suggested that patients with EXS 
have the IOP-independent risk of glaucoma. In the Thessaloniki Eye Study the 
proportion with glaucoma among EXS participants was 15.2% while the pro-
portion with glaucoma among non-EXS participants was 4.7% and in multiva-
riate analysis, the presence of EXS was a risk- factor for glaucoma (Topouzis 
2011). Investigators have evaluated the relationship between EXS and glau-
coma after adjusting for IOP in Blue Mountains Eye Study (Mitchell 1999) and 
found subjects with EXS to have 2- to 3-fold independent risk of glaucoma. 
Åström et al. (2007) in their study with long (21 years) follow-up found, that 
EXS increases the risk of glaucoma four fold. In a prospective 10-year follow-
up study, Puska found conversion to EXG in 32% in the initially EXS and 38% 
in the initially non-EXS fellow eyes, while POAG developed only in 3.5% of 
the nonEXS eyes. When initial IOP was removed from the model, the pupillary 
dilatation values (RR = 0.488; p = 0.03) and the differences in IOP between fel-
low eyes (RR = 1.224; p = 0.01) were associated with conversion to EXG 
(Puska 2002). In the Thessaloniki Eye Study where increased likelihood of 
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glaucoma development at the same IOP was investigated, it was found that the 
proportion with glaucoma for screening IOP < 20 mmHg was similar in subjects 
with or without EXS. For IOP level > 20 mmHg the proportion with glaucoma 
increased highly in subjects both with and without EXS, while it was much 
higher among those with EXS at the same screening IOP (Topouzis 2009). The 
previously mentioned studies showed that only a certain number of subjects 
with EXS develop glaucoma. The association of EXS with IOP, its differences, 
and their links to glaucoma development require additional, properly designed, 
prospective, population-based investigations. 
The prevalence of glaucoma has been found to be high in Northern Europe 
(Ringvold 1996; Ekström 2008). Hirvelä and colleagues found the prevalence of 
glaucoma to be in 12% of inhabitants aged 70 years or older in Finland (Hirvelä 
1994). Åstöm and colleagues (Åström I 2007) found a relatively high preva-
lence of glaucoma in their population study in age group of 80 years (3.2%) and 
in group 87 years (11.8%), with 4.0% and 20.5% in non-EXS and EXS groups 
respectively. The results of our study are in agreement with those findings, as 
glaucoma was significantly more frequent in the EXS group than in non-EXS 
group, 35.7% vs 11.3% respectively. In our population study, the glaucoma was 
found in 16.5% of participants. As all participants in our population-based study 
were of Finno-Ugric origin and relatively high prevalence of EXS, the findings 
could reflect true, relatively high, prevalence of glaucoma in the Estonian pop-
ulation. Exfoliative glaucoma seems to the prevalent type of glaucoma in the 
Estonian population as 50% of all glaucoma patients involved in the study had 
EXS. This is in agreement with findings in Sweden (Åström I 2007) where ex-
foliation syndrome in 59% of all glaucoma cases was found. In the CIGTS 
POAG subjects (58.0 years) were significantly younger on average than those 
with EXG (65.1 years,) (Musch et al. 2012). The high prevalence of glaucoma 
in our study could also be explained by the fact that 73.8% of participants were 
60 years or older and the median of the age of the sampling was 70 years.  
However, in the Reykjavik Eye Study Arnarsson and colleagues (Arnarsson 
2007) did not find EXS to be a risk factor for glaucoma although they did find 
higher IOP in EXS eyes. Ekström and Alm found in their study that EXS alone 
is not associated with glaucoma and there is no indication of interaction be-
tween EXS and increased IOP (Ekström & Alm 2008).  
The role of EXS in glaucoma development seems to be unclear and further 
investigations are needed to clarify this issue. It is known that the prevalence of 
glaucoma as well as EXS increases with age (Mitchell 1999; Åström II 2007). 
Nevertheless, the prevalence of glaucoma was not age-dependent in our study, 
which is not in accordance with many earlier studies (Karger 2003; Åström 
2007). One potential explanation for this finding could be the relatively small 
number of patients in the age group 80 years and older. Low participation rates 
among subjects aged 80 years and older is a common problem in population-ba-
sed studies, including herein.  
EXS is found to be associated with elastic tissue changes (Schlötzer-Schre-
hardt U & Naumann GO 2006), vascular morbidity (Mitchell 1997), coronary 
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heart disease (Sekeroglu 2008) and arterial hypertension (Miyazaki 2005). Vi-
sontai et al. found decreased cardiovagal regulation in patients with EXS (Vi-
sontai 2008). However, in our study we did not find statistically significant 
connections between EXS and any systemic disease that is in agreement with 
data from the Thessaloniki Eye Study (Anastasopoulos 2011). In a Swedish 
study with a very long follow-up period (21 years) mortality was estimated for 
each study interval but the presence of EXS did not influence the risk of death 
(Åström 2007). In Finnish population-based registry survey, no difference in 
frequency of arterial hypertension or ischaemic heart disease was noted between 
patients with POAG and EXG but the frequency of diabetes mellitus was lower 
among patients with EXG (Tarkkanen 2008). Ultrastructural and immunohisto-
chemical studies suggest that EXS involves the abnormal accumulation of elas-
tin fibres, extracellular matrix and proteoglycans (Streeten 1992; Uusitalo 1993). 
Biochemical analysis will be required to resolve questions about the disturbance 
of systemic metabolism in EXS-positive subjects, and its connections with sys-
temic conditions.  
In regression analysis, EXS did not have an impact on visual acuity, in this 
population-based study, which is in agreement with previous investigations (Puska 
& Tarkkanen 2001; Hietanen 1992). Also in CIGTS the mean visual acuity at 
baseline between POAG and EXG patients were not significant (Musch 2012). 
However, in the study of lens opacity in unilateral EXS Puska (Puska 1994) 
found significantly decreased vision in EXS-positive’s compared to EXS-nega-
tive’s, while the eyes did not differ in refraction and lens opacity.  
As with Allingham and colleagues (Allingham 2001), we did not find an as-
sociation between EXS and age-related macular degeneration.  
 
 
6.3. Exfoliation syndrome in patients  
scheduled for cataract surgery  
We found EXS in a 35.4% of cases in patients scheduled for cataract surgery, 
either in the operative or fellow eye. 47.2% of cases were bilaterally and 52.8% 
were unilaterally affected. In bilaterally phakic patients EXS was found in 
30.2% of the operative eyes, 55.4% being bilaterally and 44.6% being unilater-
ally affected. Those figures are within the same range as earlier reported in 
Finland among a similar study group, 26.5%, (Hietanen 1992). An even higher 
frequency of EXS, 42%, has been reported in Sweden in patients undergoing 
cataract surgery (Olivius et al. 1989). In a review, Forsius (Forsius 1988) re-
ported the frequency of EXS in patients with cataract to vary from 0.3% in Po-
land, 3% in France, 9% in American Indians (New Mexico) up to 18% in Nor-
way and 33% in Finland. Interestingly, in our study among patients scheduled 
for cataract surgery the prevalence of EXS was significantly higher in males in 
the age group of 50–59 years (22.2% vs. 12.5%), 60–69 years (35.7% vs. 24.1%) 
and 70–79 years (40.0% vs. 26.5%), while the prevalence was higher in females 
in the age group of 80–89 years (42.2% vs. 29.4%), but there was not a signifi-
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cant difference in the overall prevalence of EXS in the study population. The 
effect of age and gender on variables linked to EXS is shown, but the question 
remains open regarding different division of EXS in different age groups. 
Among patients scheduled for cataract surgery, there was a clear increase in the 
frequency of EXS from 17.6% in the age group of 50–59 years up to 38.6% in 
the age group of 80–89 years.  
Age is a significant risk factor for senile cataract and the incidence of cata-
ract increases with age (Taylor 1979; Hiller 1982; Krause 1988; Kozobolis 1997, 
Forsius 1988; Ringvold 1991; Hietanen 1992; Sekeroglu 2008; Obuchowska 
2006). In a cross-sectional population study, Hirvelä and colleagues recognised 
that almost two thirds of the population of 70 years of age or older had lens 
opacities. The prevalence of cataract increased with age from 44.6% in the 70- 
to 74-year-old age group to 97.6% of persons in the 85- to 89-year-old age 
group (Hirvelä 1995). In earlier studies, EXS is also shown to be a strongly age-
dependent disorder, which is seldom found before the age of 50 years 
(Tarkkanen 1962; Krishnadas et al. 2003). We did not find any patient <50 
years to have EXS. Also, Karger found an incidence rate of 2.8 per 100,000 in 
the age group of 40 to 49 years (Karger et al. 2003). In another study from 
Sweden, frequency od EXS was lower in the age group of 50–59 years (2.9%) 
in patients scheduled for cataract surgery but similar to our results in age-group 
of 80–89 years (39.2%,) (Olivius et al. 1989). It is a well known fact that the 
prevalence of EXS rises with age (Arnarsson 2007; Anastasopoulos 2011) and 
can play a role in cataract formation. It is not substantiated with natural aging 
alone. A larger prevalence figure of EXS in patients scheduled for cataract sur-
gery could be explained with a higher mean age but there can be a specific 
pathological background. In our study of patients scheduled to cataract surgery 
35.4% had EXS in the operative eye. This high percentage indicates a strong 
relationship between EXS and cataract. Increased lens opacification has also 
been noted as being associated with EXS in numerous previous studies (Taylor 
1979; Hiller et al. 1982; Puska 1994). Puska & Tarkkanen in their elegant pro-
spective study found a significant increase in opacity of the lens during a 5-year 
follow-up in EXS and non-EXS subjects but the increase was significantly 
higher in EXS eyes compared to non-EXS eyes. They found similar cluster of 
changes in patients who remained unilaterally affected; the lens opacity values 
were higher in the EXS eye compared to the fellow non-EXS eye at the end of 
the five-year follow-up (Puska & Tarkkanen 2001). Kanthan and colleagues in 
the Blue Mountain Eye Study, in a large population (3654), found similar asso-
ciations between EXS at the baseline and 10-year incidence of the cataract sur-
gery. After excluding eyes with glaucoma, the association of EXS cataract sur-
gery remained significant (Kanthan 2013). In the Thessaloniki Eye Study, the 
cataract surgery was more likely to reported in EXS participants (21%) then in 
non-EXS (11,%) (p = 0.05), adjusted for age and sex. This association remained 
significant after the exclusion of participants with glaucoma and/or glaucoma 
treatment (Anastasopoulos 2011). Furthermore, when the analysis was repeated 
using person-specific data, similar associations were observed between EXS 
46 
 
and cataract surgery. On the other hand, no significant associations were obser-
ved between EXS at baseline and the long-term progression of the different 
cataract type, including nuclear, (Kanthan 2013). An association between EXS 
and cataract is biologically feasible, as in the EXS eyes the blood-aqueous bar-
rier is impaired (Küchle 1996) and the rate of aqueous flow through the anterior 
chamber is lower compared to the non-EXS eyes (Johnson 1982) but lens me-
tabolism depens on the aqueous. Further investigations are needed to clarify the 
genomic and proteomic background and connections of these two pathologies.  
In our study, among patients scheduled for cataract surgery, the predominant 
type of lens opacity in the operative eyes with EXS differed significantly from 
those without EXS (Table 7). In both clinical and histopathological studies, the 
predominant type of cataract in EXS has been shown to be nuclear sclerosis, 
while cortical and supranuclear cataracts are less common and severe in EXS 
(Seland & Chylack 1982, Hietanen 1992, Sekeroglu 2008, Kanthan 2013). This 
finding was confirmed in the present study, 57.6% of all eyes with EXS sched-
uled for cataract surgery had nuclear cataract, which is similar with findings of 
earlier studies (Young 2004; Arvind 2003; Hietanen 1992). We found the same 
trend in our population-based cross-sectional study. Also, in a Finnish cross-
sectional population-based study, stepwise logistic regression analysis indicated 
that the only risk factor for cortical cataract to be age and the risk factors for 
nuclear sclerosis to be age and exfoliation (Hirvelä 1995). In recently published 
long-term follow-up data from The Blue Mountains Eye Study suggest that the 
presence of EXS is associated with an increased risk of nuclear cataract (OR 
1.90; 95% CI 1.04–3.48) and cataract surgery (Kanthan et al 2013). The finding 
that posterior subcapsular cataract is more common in patients without EXS 
than in those with it (Seland & Chylack 1982; Hietanen et al. 1992; Puska 1994) 
was confirmed in our study (19.7% vs. 6.5%). On the other hand, Krishnadas 
and colleagues (Krishnadas 2003) found that EXS was associated with posterior 
subcapsular and cortical cataract. Nuclear cataract, like EXS, was also shown to 
be highly age-related but not causally related to EXS in the Reykjavik Eye 
Study (Arnarsson 2007). The relationship between EXS and different types of 
cataract needs further investigations. Both conditions, EXS and cataract, can 
have similar pathophysiological backgrounds as oxidative stress (Schlötzer-
Schrehardt 2010) and decreased antioxidant defence (Erdurmuş 2011). A rela-
tively high percentage of mature cataracts (11%) were found in this material in 
comparison to 1.7% in an earlier study, (Hirvelä 1995). The economic situation 
in Estonia can explain the high percentage of mature cataracts to some extent, 
but 2/3 of patients (21 out of 33) had EXS of those patients. Sekeroglu and 
colleagues found same trend, 24.6% of all mature cataracts had EXS, in their 
study (Sekeroglu 2008). 
The operative eyes with and without EXS preoperatively did not differ in 
pupil diameter (4.0 vs. 4.2 mm, p = 0.139), but mydriasis was less in eyes with 
EXS than in those without EXS (6.4 vs. 7.2 mm, p < 0.0001). The poorer re-
sponse to mydriatics in eyes with EXS compared to those without EXS was 
confirmed in this study (Tarkkanen 1986; Puska 1995). Similarly to our find-
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ings in patients scheduled for cataract surgery, Wirbelauer (Wirbelauer et al. 
1998) and Shastri (Shastri et al 2001) found significantly poorer mydriasis in 
EXS-eyes. Insufficient mydriasis is important risk-factor in cataract phacoemul-
sification, especially in patients with EXS due to weak zonules and possible 
subluxation of the lens (Skuta 1987). Odds ratio for intra-operative complica-
tions (vitreous loss, capsular break, zonular break) is estimated to be 5.1 for 
EXS that is present as opposed to when it is absent (Scorolli 1998).  
In regression analysis EXS did not have an impact on visual acuity in pa-
tients scheduled for cataract surgery, which is in agreement with previous in-
vestigations (Puska & Tarkkanen 2001; Hietanen 1992).  
In the present study, the mean preoperative IOP was significantly higher in 
the operative eyes with EXS than in those without it (19.2 +6.5 vs. 17.1 +3.8 
mmHg, p = 0.006). After pupil dilatation, IOP remained at a higher level in eyes 
with EXS when compared to eyes without EXS (18.6 + 7.3 vs. 16.4 + 4.1 mmHg, 
p = 0.013). In earlier studies conducted on patients scheduled for cataract sur-
gery, the findings are similar; there are tendency to higher IOP in patients with 
EXS compared those without it (Hietanen 1992; Shastri 2001; Shingleton 2003; 
Teshome 2004; Sekeroglu 2008). However, Wirbelauer in his two different 
studies found no difference between those two groups in pre- and postoperative 
IOPs in cataract patients (Wirbelauer 1998; 1998b).  
Also, in our study, glaucoma was significantly more frequent in eyes with 
exfoliation (27.8%) than in those without it (9.6%). In earlier studies, the prev-
alence of glaucoma in eyes with EXS has been found to vary considerably, 
roughly half of the EXS eyes being glaucomatous (Aasved 1971; Karger et al. 
2003; Tarkkanen 1962). In a study conducted by Hietanen and colleagues, in 
patients scheduled for cataract surgery, a history of glaucoma was recorded in 
33.8% of patients with EXS and in 10.1% of non-EXS patients (p < 0.001). 
Thirty-one percent of patients with EXS and 7% of patients without EXS had 
medical treatment for high IOP preoperatively. Irrespective of their treatment, a 
trend to higher preoperative IOP was seen in patients with EXS compared to 
those without it (Hietanen 1992). 
In our study forty-five (14.8%) patients had glaucoma in the eye scheduled 
for cataract surgery, and of these 25 (8.2%) patients had glaucoma in both eyes. 
Four (1.3%) patients had glaucoma only in the fellow eye. As in our population-
based study, in patients scheduled for cataract surgery glaucoma was signifi-
cantly more frequent in eyes with EXS than in those without it. Of all glaucoma 
cases, EXG embraced 54.4% (in an operative eye 63.3%). The figure is similar 
to that reported earlier in Northern Europe (Tarkkanen 1962; Ringvold et 
al.1991; Hirvelä et al. 1995). 
EXS as a risk factor for glaucoma is wellknown fact and it warranted in our 
study. We found in bilaterally phakic eyes with unilateral EXS (n = 41) glau-
coma was recorded in 31.7% EXS and in 14.6% non-EXS eyes. Similar results 
had Hirvelä and colleagues in their study were they found that persons with 
EXS in one or both eyes, glaucoma was found in 27%, and in 8% in the non-
EXS group (Hirvelä 1995). Hyman and colleagues found in the Early Manifest 
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Glaucoma Trial that eyes with EXG have significantly higher IOPs compared to 
POAG (Hyman et al. 2010). Similar findings had Konstas in his study, in com-
parison with POAG, patients with EXG had higher untreated IOP and higher 
IOP with medical therapy (Konstas 1993), and EXG patients have greater diur-
nal IOP fluctuations (Konstas 1997). The influence of IOP and its fluctuation 
for cataract formation merit further investigations.  
Somewhat surprisingly, in our material we found no difference in the mean 
IOP between patients with EXG or with primary open-angle glaucoma (20.6 vs. 
21.0 mmHg, p = 0.507). OHT was found in 31 (10.2%) operative eyes of which 
16 (51.6%) eyes were affected and 15 (48.4%) were without exfoliation, with 
do difference between two groups. Nevertheless, Arvind found the prevalence 
of OHT to be significantly higher in the EXS-positives (Arvind 2003). Also 
Anastasopoulos with colleagues in the Thessaloniki Eye Study found significant 
percentage of EXS-positives having IOP > 22 mmHg compared to those with-
out EXS (Anastasopoulos 2011).  
The presence of EXS and EXG found to be unfavourable prognostic factors 
in cataract surgery (Naumann 1998). 
 
 
6.4. Exfoliation syndrome as a risk factor for corneal 
endothelial cell loss in cataract surgery 
Several studies in normotensive patients with senile cataract have demonstrated 
quantitative or qualitative morphological changes in corneal endothelium in 
patients with EXS (Wirbelauer 1998; Wirbelauer 1997; Inoue 2003). In a simi-
lar patient’s group, Miyake et al. observed a decrease of hexagonality and an 
increased coefficient of variation (Miyake 1989). Observations of these studies 
suggest that the corneal endothelial changes represent a consistent finding in 
eyes with EXS and in patients with EXS keratopathy only moderate rise in IOP 
or intraoperative factors can lead to the corneal decompensation. Those poten-
tial changes can be amplified by insufficient mydriasis and zonular instabilities. 
On the other hand, Puska et al. (Puska 2000) did not find quantitative or quali-
tative morphological changes in corneal endothelium in comparing the cornea 
in both eyes of normotensive patients with unilateral EXS.  
Previous studies have found that corneal endothelial cells have decreased 
cell density, an increased the coefficient of variation of the cell area, and de-
creased the percentage of hexagonal cells with increasing age (Abib 2000; In-
oue 2003). Physiological reduction in endothelial cells due to ageing has been 
estimated to be 0.5–0.6% per year with a gradual increase in polymegethism 
and pleomorphism (Bourne 1994; 1997). Age has been found to be an important 
variable to relevant to ECD in cataract surgery (Inoue 2002; Küchle 2000).  
Stefaniotou et al. found significantly lower cell density in the EXS group 
than in the controls, which had no ocular disease other than senile cataract, but 
there was no difference between the eyes with EXS and normal fellow eyes 
(Stefaniotou 1992). Wirbelauer in two different studies of normotensive patients 
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scheduled for cataract surgery found a significant reduction of total ECD in 
patients with EXS (Wirbelauer 1997; 1998). Regional morphometric data re-
vealed reduced ECD in central and paracentral region in patients with EXS 
compared to non-EXS patients, which suggests diffuse endothelial cell reduc-
tion in central and paracentral areas in patients with EXS (Wirbelauer 1998). 
Moreover, in patients with EXS without previous surgery on the other eye the 
endothelial variables revealed a similar pattern with reduced total ECD com-
pared to controls (Wirbelauer 1998). Inoue with colleagues found also that ECD 
was significantly lower in patients with EXS, but they did not place significant 
difference between the pleomorphism and the coefficient of variation in the cell 
area in the EXS-patients and controls (Inoue 2003). Our results suggest, contra-
rily to some mentioned previous studies, that preoperative ECD do not differ 
significantly in cataractous patients with or without EXS, centrally (2543 vs 
2593 resp), or paracentrally (2480 vs 2455 resp). Preoperatively, we did not find 
differences in the coefficient of variation and hexagonal cells between two 
groups. This is in accordance with recent study conducted by Cankaya and col-
leagues (Cankaya 2012). In a study by Puska and colleagues in non-glaucoma-
tous, normotensive subjects, similar to our results, found that eyes with or with-
out EXS did not differ in ECD and in the coefficient of variation of cell size or 
pleomorphism (Puska et al 2000). Also, Østern & Drolsum did not find signifi-
cant differences in ECD, pleomorphism and polymegethism between two, EXS 
vs non-EXS, groups (Østern & Drolsum 2012).  
There is no consensus in data from literature about the direct harmful impact 
of EXM on corneal endothelial cells.  
In the first postoperative day, we found a statistically significant difference 
in paracentral but not in central endothelial cell loss between the EXS and non-
EXS groups. The decrease of the central ECD was 9.8% in the EXS group and 
9.5% in the non-EXS group, while it was 8.2% in the EXS and 1.1% in the non-
EXS group paracentrally. Similar to our findings, Wirbelauer found central and 
paracentral cell loss occurred more homogenously over the entire cornea in the 
EXS group, reducing the ECD by 10.6% and 11.3%, while the similar decrease 
was 6.1% and 12.2%, respectively, in the non-EXS group (Wirbelauer 1998). 
Our findings are in line with the results of Wirbelauer, (Wirbelauer 1998) who 
found a similar total decrease of ECD without a significant difference between 
two groups. This endothelial cell loss reflects an immediate surgical effect, and 
stabilization with mild decrease of the ECD was observed at the end of one-
month follow-up in both groups. 
One month after the surgery, ECD was more affected centrally as well as pa-
racentrally in the EXS group than the non-EXS group but not statistically sig-
nificantly. In the operated eyes, the total ECD was significantly lower in EXS 
and non-EXS patients compared to preoperative with not a significant differ-
ence between the two groups, which is in accordance with Wirbelauer et al. 
(Wirbelauer 1998). Compared to our results, Wirbelauer (Wirbelauer 1998) found 
a similar extent of postoperative decrease of ECD at the end of the follow-up. 
Also, in a study, by Østern & Drolsum with a long follow-up time (6–7 years), 
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with relatively large number of cataract patients at the end of the follow-up 
(45), they found no pre- and postoperative differences in ECD, between EXS 
and non-EXS group, in the end of follow-up (Østern & Drolsum 2012).  
Walkow and colleagues conducted a study, on normotensive non-EXS pa-
tients, where they evaluated the possible effect of the location of the corneo-
scleral tunnel incision on total and localized endothelial cell loss after phaco-
emulsification. They found no significant differences in the central or in the 
area localized in the quadrant of the positions of the corneal surgical site 
(Walkow 2000). This finding consequentially supports our results after a one-
month follow-up that ECD during cataract phacoemulsification is homoge-
nously affected, despite of differences in the first postoperative day.  
In our study, in patients scheduled for cataract surgery, as in a number of pre-
vious investigations (Scorolli 1998; Shingleton 2003; Pohjalainen 2001) patients 
with EXS were significantly older than the controls. To evaluate the influence 
of aging and EXS to ECD, we performed regression analysis with age and EXS 
as covariates. After one month of regression analysis, we found significant nega-
tive association between the age of patients and the postoperative central as well 
as overall ECD (r2 = 0.47, p = 0.004; and r2 = 0.45, p = 0.004, respectively). 
We found that in both groups, in patients with or without EXS, age was the most 
significant factor associated with higher cell loss during cataract surgery inde-
pendently from EXS or other variables. In elderly people, the overlapping syn-
ergy of aging and EXS can lead to pronounced metabolic interferences of cor-
neal endothelium and stroma and further studies are needed to clarify this issue.  
Puska found that eyes with EXS had higher values for CCT than the fellow 
non-EXS eyes in normotensive patients with unilateral EXS (Puska 2000). On 
the contrary, Inoue in a study with EXS patients, with or without glaucoma, 
found CCT in the EXS eyes to be significantly thinner than that of the non EXS 
control patients, regardless of the presence of glaucoma (Inoue 2003). Ozcura et 
al in a study in EXS patients, with or without glaucoma, who were compared to 
age-matched non-EXS patients, found that the mean CCT was significantly 
thinner in all EXS and nonglaucomatous EXS eyes compared to controls. Oz-
cura also found that the mean CCT reading did not differ between EXS and non-
EXS fellow eyes (Ozcura 2011). Stefaniotou et al. in turn found significantly 
thicker corneas in the EXS group than in the controls and, similarly to last men-
tioned study, there was no difference in patients with unilateral EXS between 
the eyes with EXS and normal fellow eyes (Stefaniotou 1992). In our study, the 
mean preoperative CCT values did not differ significantly between the EXS and 
non-EXS group, which is in accordance with Cankaya et al. and Østern & Drol-
sum study (Cankaya 2012; Østern & Drolsum 2012). No significant differences 
between groups in CCT were found during the follow-up to our study.  
In the first postoperative day, a significant increase of the CCT was recorded 
in EXS and non-EXS eyes due to corneal oedema but there was no significant 
difference between values of CCT at baseline and after one month. Similar 
findings had Ventura and colleagues in their non-EXS study group where all 
patients had significant corneal swelling on the first postoperative day which 
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was restored to preoperative values by 3 and 12 months, even in patients in 
whom significant endothelial cell loss occurred (Ventura 2001). Similar to 
many other studies (Inoue 2003; Ventura 2001), we did not find a correlation in 
regression analysis between endothelial cell loss and CCT in any follow-up time 
point. However, Lundberg in the study on nonEXS patients, found a strong cor-
relation between corneal swelling in the first postoperative day and ECD loss 
after phacoemulsification cataract surgery (Lundberg 2005). There is no con-
sensus in literature regarding the potential influence of EXS on CCT. Moreover, 
the results of different studies are contradictory. We can conclude, based on the 
results of our study that the presence of EXS, in cataract phacoemulsification, 
does not significantly affect CCT. 
During cataract phacoemulsification the relationship between endothelial cell 
loss and morphometric parameters of the eye as well as parameters of surgical 
procedure has been evaluated in several studies. Different preoperative factors 
can have unequal power of significance in patients with and without EXS in 
interaction with intra- and postoperative factors. Walkow and colleagues found 
the age to be an important factor to cell loss only with correlation with lens 
thickness and longer operation time (Walkow 2000). They also found a signifi-
cant correlation between endothelial cell loss and axial length, but not between 
endothelial cell loss and anterior chamber depth. Contrarily, Küchle et al. found 
a significant relationship in cataract surgery between ACD and endothelial cell 
loss in patients with EXS but not between AL and ECD (Küchle 2000).  
In our study, no correlation between AL, ACD, keratometry, lens thickness 
and pre- and postoperative ECD was found not in EXS or in non-EXS group. 
Although a shallow anterior chamber and short axial length could dispose a re-
duction of endothelial cells in cataract surgery, we believe that surgeon tech-
nique and the phaco settings used are more important. We found, in regression 
analysis, in our study that the age of the patient was the most significant factor 
associated with higher cell loss during cataract surgery independently from EXS 
or other preoperative variables.  
Wirbelauer in his study did not find differences in phaco power between 
EXS and nonEXS-patients, and phaco power did not have an influence to ECD 
in his study (Wirbelauer 1998). Contrary to results of mentioned study, we 
found in our study, among intraoperative parameters, that the phaco power was 
significant variable for ECD loss and, similarly, the presence of EXS did not 
affect ECD in regression analysis.  
Walkow and colleagues in their study found phaco time to be the most sig-
nificant intraoperative factor in endothelial cell loss (Walkow 2000). In our 
study, there was a significant difference between the two groups in phaco time, 
which could be explained by more cautious surgical technique in EXS eyes due 
to insufficient mydriasis and zonular weakness. In our study, we also measured 
volume of balanced salt solution used during the operation and found that it was 
used significantly more in EXS-cases, which can also partly be explained with 
longer phaco time. The overall operation time was also longer in our study in 
EXS-cases but not significantly. Wirbelauer, contrarily, did not find differences 
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in phaco time in EXS and non-EXS-patients, and this variable did not have an 
influence to ECD in their study (Wirbelauer 1998). Similar to the last men-
tioned study, we did not find a direct relationship between phaco time and ECD, 
but time became significant in interaction with phaco power. Moreover, in re-
gression analysis EXS in interaction with overall phaco impact (phaco time 
multiplied with power) had a significant influence on endothelial cell loss. This 
indicates that EXS in high phaco impact cases (e.g. hard nucleus) significantly 
increases the risk of endothelial cell loss.  
In patients scheduled for cataract surgery, the mean preoperative IOP was 
significantly higher in the operative eyes with EXS than in those without it. 
Hietanen found the same trend in her study in patients scheduled in cataract 
surgery (Hietanen 1992). Patients with EXS also have tendency to have ele-
vated postoperative IOP and IOP spikes (Pohjalainen 2001; Levkovitch-Verbin 
2008). Similar to other studies (Pohjalainen 2001; Lagreze 1996), we found a 
significant rise of IOP in the first postoperative day, which returned to the base-
line value over the course one month.  
Pohjalainen and colleagues in their study where they compared postoperative 
IOP of EXS versus non-EXS patients after phacoemulsification found normal-
ised pressure as soon as one week after the cataract surgery with no differences 
between two groups (Pohjalainen 2001). Levkovitch-Verbin and colleagues 
found a similar reduction of postoperative IOP elevation in EXS eyes (Levko-
vitch-Verbin 2008). Results from our study confirm those findings that patients 
with EXS have a tendency towards a postoperative rise of the IOP but not 
significantly compared to the control group. The IOP postoperative peak is tran-
sient, with not a significant difference between two groups and it does not have 
a significant influence on endothelial cell damage. However, there is a study 
from Germany in which Wirbelauer with colleagues did not find, in similar pa-
tient groups, a significant IOP rise in the first postoperative day in EXS or in 
non-EXS patients (Wirbelauer 1998b). They also found a similar decrease of 
postoperative IOP, compared to preoperative, in both exfoliative and nonexfoli-
ative groups after 1 and 6 month follow-ups (Wirbelauer 1998b). In our study, 
in one month after surgery, there was postoperative decrease of IOP (compared 
to pre-operative) in EXS-group but it did not reach statistical significance. 
There is a retrospective study which comprised of the analysis of 1,122 eyes 
with EXS and found long-term IOP reduction, 7-years follow-up, after cataract 
removal on EXS eyes with or without glaucomatous changes (Shingleton 2008). 
Also Damji et al. found in their prospective study that IOP decreases more in 
EXS-positives after cataract phacoemulsification compared to control eyes 
without EXS. This effect was more pronounced in glaucoma patients and per-
sists for at least 2 years (Damji 2006). Regression analysis of our data showed 
that pre- and postoperative IOP did not have an effect on ECD in both groups, 
which is in accordance with most previous studies. The results of our study 
confirmed that perioperative IOP fluctuation in patients with EXS do not affect 




1. Our cross-sectional population-based study showed the high prevalence of 
EXS in Estonia and that it increases with age. The overall prevalence of EXS 
was 25.5%, which is at the same level as Nordic countries. In a regression 
analysis, adjusted for age, we found significant, 1.5-fold, impact of EXS on 
cataract formation. 
2. Patients with EXS have tendency to have higher IOP compared to non-EXS 
patients. Glaucoma was significantly more frequent in the EXS group com-
pared to non-EXS patients. 
3. We found EXS in 35.4% of eyes in patients scheduled for cataract surgery. 
This finding is also similar to that reported earlier in Northern Europe.  
4. We found string relationship. The results of our study are in agreement that 
nuclear cataract is prevalent in patients with EXS. We found strong relation-
ship between EXS and cataract. 
5. We found the age to be the most important parameter in endothelial cell loss 
in patients with and without EXS. Exfoliation syndrome independently did 
not affect ECD in regression analysis. Phaco power was the most affective 
intraoperative variable to endothelial cell loss. Although endothelial cell loss 
was more expressed in the EXS group than in the non-EXS group, the sta-
tistically significant negative correlation was only determined in interaction 
with the overall phaco impact.  
 
The widespread prevalence of EXS in Estonia requires attention in everyday 
clinical practice to diagnose and treat patients with ocular hypertension, glau-
coma and cataract in time. EXS can be easily overlooked as in 15% of patients 
EXS was noted only after pupil dilatation. Demands for high quality cataract 
surgery do not allow us to underestimate the potential complications caused by 
EXS. An experienced surgeon using a highly adhesive viscoelastic agent should 





SUMMARY IN ESTONIAN 
Eksfoliatsiooni sündroomi levimus Eestis ja selle kliiniline tähendus 
 
Sissejuhatus: 
Eksfoliatsiooni sündroom (EXS), tuntud ka pseudoeksfoliatsiooni nime all, on 
east sõltuv krooniline haigusseisund, mida iseloomustab fibrillaarse ekstratsellu-
laarse materjali produktsioon ja progresseeruv kuhjumine silmamuna eesmises 
segmendis. Silma vaatlusel on nähtav silma eesmises segmendis miniatuurset 
kõõma meenutav materjal, mis tüüpiliselt sadeneb läätse eesmisele pinnale, pupil-
laaräärisele ja eeskambri nurka. Iseloomulik on ka pupillaaräärise depigmentat-
sioon. Esimesena kirjeldas seda fenomeni ja käsitles teaduslikel alustel Soome 
oftalmoloog John G. Lindberg. Eksfoliatiivset materjali on leitud ka väljaspool 
silmamuna: tagumistel tsiliaararterites ja vorteksveenides aga ka vistseraalsete 
organite sidekoes. 
Tõusnud silma siserõhk on sage tüsistus EXS-i esinemisel. EXS-patsientidel 
on mitmekordne risk haigestuda püsivasse okulaarsesse hüpertensiooni ja glau-
koomi. 
Avatud eeskambri nurgaga glaukoomi koosesinemisel EXS-ga nimetatakse 
haigust eksfoliatiivseks glaukoomiks. Seda haigust iseloomustavad sagedase-
mad ja suuremas ulatuses silma siserõhu kõikumine, ning märksa agressiivsem 
haiguse kulg. Samuti on iseloomulik tõrksam allumine medikamentoossele ra-
vile kui sagedasem vajadus kirurgilise ravi järele.  
On täheldatud katarakti sagedasemat esinemist EXS-patsientidel. Tuleb siis-
ki tunnistada, et selgeid põhjuslikke seoseid ei ole tõestatud kuna tegu on mõle-
mal juhul east sõltuva seisundiga. Küll on EXS-i puhused muutused nagu hal-
vasti laienev pupill, zinni jätkete ja läätse kapsli nõrkus riskifaktoriteks intra-
operatiivsete tüsistuste nagu kapsli rebenemine ja klaaskeha hernia tekkel.  
Uuringud on näidanud kvantitatiivseid ja kvalitatiivseid muutusi silma sarv-
kesta endoteelis. EXS-positiivsetel on leitud sarvkesta endoteeli rakkude tihedus 
olema madalam võrrelduna EXS-negatiivsetega. On sedastatud muutusi rakku-
de heksagonaalsuses ning tõusnud on rakkude suuruse variatsiooni koefitsient. 
Need iseloomulikud muutused on predispositsiooniks endoteelirakkude kahjus-
tusele silmakirurgias, sealhulgas ka katarakti operatsioonil. 
 
Epidemioloogia: 
Kuigi EXS esinemine on ülemaailmne võib täheldada selle esinemissageduse 
küllalt suur erinevust eri piirkondade vahel. Siiani läbiviidud uuringud ei ole 
teostatud ühetaolise metoodikaga ja seetõttu on keeruline eri uuringutest saadud 
andmeid omavahel võrrelda.  
Avastamisest alates on EXS-i, seoses sealse sagedasema esinemisega, peetud 
nn Skandinaavia sündroomiks. Esinemissagedus varieerub 0% inuiitidel 1,7%-ni 
Kongos, 3,4%-st Jaapanis 5,5%-ni Pranstusmaal, 9,0%-st Leedust 11,9%-ni 
Kreekas kuni 25,3%-ni soomlastel. Erinevad uuringud on leidnud ka küllalt 
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erinevat EXS-i esinemist eri sugupoolte vahel. Mitmetes uuringutes on viidatud 
võimalikule geneetilisele predisponeeritusele EXS-i esinemisel.  
 
Eksfoliatiivne materjal: 
Praeguste seisukohtade kohaselt on EXS-i puhul tegu elastsete mikrofibrillide 
moodustumisega mis agregeeruvad tüüpiliseks konfiguratsiooniks üle ensümaa-
tilise ristseotuse. Eksfoliatiivse materjali (EXM) koostises on elastiini, tropoe-
lastiini, laminiini, amüloid P, vitronektiini ning elastsete mikrofibrillide kompo-
nente. Eksfoliatiivse materjali (EXM) tekke ja migratsiooni kohta on erinevad 
teooriad. Migratsiooni-teooria järgi on EXM tekkinud mittepigmenteeritud rips-
lihase epiteelis ja iirise veresoonte seintes ja ladestub siis läätse kapslile ja mu-




EXS-i iseloomustab spetsiifilise valkja, kõõma meenutava, helbelise materjali 
moodustumine üle kogu silma eesmise segmendi. EXM ladestub iirise äärisele, 
eeskambri nurka ja sarvkest endoteelile. EXM ladestub ka läätse eeskapslile 
moodustades seal spetsiifilise tsentraalse diski ja perifeerse vöö. Esineb ka pig-
mendi dispersiooni iirise tagumiselt lestmelt, olles sellega eeskambri nurga pig-
menteerumise peamiseks põhjuseks. EXS-ga kaasnevad ka silma eesmise seg-
mendi vaskulaarsed muutused peamiselt iirisel ja limbuse piirkonnas põhjusta-
des hüpoperfusiooni ja hüpoksiat. 
Eelnevad uuringud on andnud küllalt vastukäivaid andmeid sarvkesta endo-
teeli rakkude tiheduse kohta EXS-positiivsetel. On näidatud EXS-positiivsetes 
silmades sarvkesta endoteeli rakkude tiheduse olema madalam võrrelduna EXS-
negatiivsetega. Samas ei ole erinevust rakutiheduses võrrelduna sama patsiendi 
EXS-negatiivse kaassilmaga. On ka mitmeid uuringuid kus ei ole leitud mingeid 
erinevusi EXS-positiivsete ja -negatiivsete vahel. Analoogselt endoteeli rakkude 
tihedusele on andmed vasturääkivad ka sarvkesta paksuse osas. On leitud nii 
õhemaid kui paksemaid sarvkesti EXS-positiivsetel võrrelduna EXS-negatiiv-
setega.  
EXS on praeguste teadmiste järgi organismi süsteemne protsess millel esineb 
peamiselt silmapoolne haaratus. Tegemist on histoloogiliselt kahepoolse aga klii-
niliselt sageli ühepoolselt väljendunud protsessiga. Diagnoosimise hetkel on 
EXS leitav kolmandikul patsientidest. Uuringus, milles jälgiti unilateraalse esi-
nemisega patsiente kümne aasta jooksul, leiti protsessi muutus kahepoolseks 
38%-l juhtudest. Sealjuures ei tuvastatud mingeid protsessi mõjutavaid riskifak-
toreid. 
Enamus uuringutes, vaid üksikute eranditega, on tuvastatud olulistelt kõrgem 
silma siserõhk EXS-positiivsetel võrrelduna EXS-negatiivsetega. Tõusnud sil-
ma siserõhk on hästi tuntud glaukoomi riskifaktor. Samas mitte kõikides EXS-
positiivsetes silmades ei ole silma siserõhk tõusnud ja ei kujune välja glaukoo-
mi. Siiski tõstab EXS-i esinemine glaukoomi haigestumise riski 4–6 korda. 
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On tõendeid, mis viitavad EXS-i olulisele rollile katarakti moodustumisel. 
Silma läätse ainevahetus on otseselt sõltuv silmasisesest vesivedelikust ja selle 
metabolismist. Tõusnud või kõikuval silma siserõhul võib olla siin oluline roll 
katarakti moodustumisele kaasaaitamisele.  
Nii histoloogilised kui kliinilised uuringud on näidanud, et sagedamini esine-
vaks katarakti alatüübiks EXS-positiivsetel on nukleaarne katarakt. 
 
EXS ja katarakti kirurgia: 
EXS-i puhused sümptomid nagu halvasti laienev pupill, lõdvad zinni jätked, 
rabedam läätsekapsel tõstavad lõikustüsistuste riski ning võivad mängida olulist 
rolli lõikuse lähi- ja kaugtulemustele. Samuti on vigastusaltim sarvkesta endo-
teel. 
 
EXS ja süsteemsed haigused: 
EXM sarnast materjali on leitud EXS-positiivsetel vistseraalsete organite side-
koes. EXM-i on leitud südamest, kopsudest, maksast, sapipõiest ja neerudest aga 
ka peaaju veresoonte seintest. EXS-positiivsetel on leitud kõrgem transitoorsete 
isheemiliste atakkide, arteriaalse hüpertensiooni ja müokardi infarkti esinemis-
sagedus. Samas on uuringuid kus selliseid seoseid leitud ei ole. EXS süsteemne 
tähendus vajab täiendavaid süstemaatilisi uuringuid.  
 
Käesoleva teadustöö eesmärgiks: 
 oli teada saada EXS-i esinemissagedus Eesti populatsioonis, hinnata silma 
siserõhku ja glaukoomi esinemist EXS-ga ja EXS-ta isikutel; hinnata EXS-i 
esinemist katarakti lõikuseks saabunutel, 
 hinnata EXS-i kui potentsiaalset riskifaktorit läätse tuhmumisel, 
 katarakti lõikuse, fakoemulsifikatsiooni, pre- intra- ja postoperatiivsete muu-
tujate mõju sarvkesta endoteelile ja sarvkesta paksusele EXS-ga ja EXS-ta 
patsientidel. 
 
Uurimistöö aluseks olevates uuringud viidi läbi Helsingi Deklaratsiooni printsii-
pe silmas pidades. Kõik uuringud said kinnituse Tartu Ülikooli Eetikakomiteelt. 
Kõik osalenud andsid kirjaliku teavitatud nõusoleku uuringus osalemiseks. 
Kõik uuritavad vaadati läbi ühe uurija, Kuldar Kaljurand, poolt. Kõik lõiku-
sed viis läbi prof. Pait Teesalu fakoemulsifikatsiooni meetodil. Lõikuse käigus 
paigaldati läätse kapslikotti intraokulaarne kunstlääts. 
 
Eksfoliatsiooni sündroomi esinemissagedus Eestis: 
Populatsiooni-põhine, läbilõike uuring viidi läbi juhusliku valimi alusel, (Eesti 
Rahvastikuregister) Tartu linna elanike hulgas. Uuritavad olid viiskümmend 
aastat või vanemad ja jaotatud kümne aasta kaupa gruppidesse. Kõik patsiendid 
olid soome-ugri päritolu. Osales 424 isikut, kellest 65,3% olid naised ja 34,7% 
olid mehed. Uuringus osalemiseks nõusoleku andnud isikutele teostati oftalmo-
loogiline läbivaatus Tartu Ülikooli Silmakliinikus. EXS-i esinemine ja, olemas-
olul, katarakti alatüüp sedastati müdriaasi järgselt. 
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Eksfoliatsiooni sündroomi esinemine katarakti operatsiooniks saabunuil:  
Prospektiivne uuring viidi läbi 305 katarakti lõikuseks saabunud eelselektsioo-
nita patsiendi hulgas. Katarakti fakoemulsifikatsiooni-meetodil läbiviidud lõi-
kus viidi läbi Tartu Ülikooli Silmakliinikus. Lõikuspäeva hommikul läbisid kõik 
uuritavad põhjaliku oftalmoloogilise läbivaatuse. Silma siserõhk ja pupilli läbi-
mõõt mõõdeti enne ja pärast müdriaasi samades valgustingimustes. EXS-i esi-
nemine ja katarakti alatüüp sedastati müdriaasi järgselt.  
 
Eksfoliatsiooni sündroom kui riskifaktor sarvkesta endoteeli kahjustuseks 
katarakti kirurgias:  
Prospektiivne, kohort-uuring milles osales 37 EXS-positiivset ja kontrollgrupis 
37 EXS-negatiivset patsienti viidi läbi Tartu Ülikooli Silmakliinikus katarakti 
operatsiooniks saabunuil. Eelnev silma trauma või operatiivne ravi, suur lühi-
nägevus, uveiit anamneesis ning sarvkest muud anomaaliad olid aluseks patsien-
di uuringusse mittearvamisele. Kõikidel uuritavatel mõõdeti optilise telje pikkus, 
eeskambri sügavus, läätse paksus ning teostati keratomeetria. Sarvkesta paksus 
ning endoteeli rakutihedus mõõdeti peegel-mikroskoobi abil. Endoteelist tehti 
ülesvõte 0,1x0,1 mm alal ning loendati rakkude hulk, hinnati rakkude suurust 
ning määrati variatsiooni koefitsient. Ülesvõtted tehti viies positsioonis: tsent-
raalselt, üleval, all, nasaalsel ja temporaalsel 6 mm diameetriga alal. Sel kombel 
hinnati sarvkesta paksust ja endoteeli rakkude seisundit lõikuse eelselt, vahetult 
lõikusele järgneval päeval ja ühe kuu möödumisel lõikusest. Lõikuse eelselt 
sedastati katarakti alatüüp. 
 
Tulemused: 
EXS-i levimus Eestis on 25,5% viiskümmend aastat ja vanematel isikutel. Kahe-
poolne haaratus sedastati 33,3%-l EXS-positiivsetest. EXS-i esinemissagedus 
tõusis eaga oluliselt. Puudus sugudevaheline erinevus EXS-i esinemisel. EXS-
positiivsetel oli oluliselt kõrgem silma siserõhk nii enne kui pärast pupilli laien-
dust. Glaukoom diagnoositi 16,5%-l uuringus osalejatest ning glaukoom oli olu-
liselt sagedamini EXS-positiivsetel, vastavalt 35,7% ja 11,3%. Erinevalt EXS-st 
ei olnud glaukoomi esinemine east sõltuv. Läätse muutused esinesid 41,5%-l 
patsientidest, olulise erinevusega EXS-positiivsete (57,0%) ja EXS-negatiivsete 
(39,5%) vahel. Regressiooni analüüsil andis EXS, east sõltumata, 1,5-kordse 
riski katarakti tekkeks. Populatsiooniuuringus ei olnud erinevust nägemisteravu-
ses eri gruppide vahel. 
Katarakti operatsiooniks saabunuil esines EXS 35,4%-l juhtudest. Kahepool-
ne haaratus esines 47,2%-l patsientidest. Viieteistkümnel protsendil patsienti-
dest oli EXS sedastatav vaid läätse eeskapslil perifeerse vööna ja nähtav vaid 
maksimaalses pupilli laienduses. Müdriaas oli oluliselt väiksem EXS-positiivse-
tes silmades. Oodatavalt oli EXS-positiivsetel kõrgem silma siserõhk võrreldes 
EXS-negatiivsetega, mis säilis ka müdriaasi järgselt. Opereeritavates silmades 
esines kaashaigusena glaukoom 14,8%-l juhtudest ja neist 54,4%-l oli tegu eks-
foliatiivse glaukoomiga. Opereeritavates silmades oli EXS-positiivsetel domi-
neerivaks katarakti alatüübiks nukleaarne katarakt samal ajal kui EXS-nega-
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tiivsetel olid eri alatüübid märksa ühtlasemalt jaotunud. 41,3%-l kõikidest küp-
setest kataraktidest olid EXS-positiivsed. 
Katarakti lõikuseks saabunuil ei olnud olulisi erinevusi lõikuseelses sarv-
kesta endoteeli rakutiheduses kahe uuringugrupi vahel. Keskmine tsentraalne 
rakutihedus oli vastavalt 2543 (+417) ja 2594 (+519) EXS-positiivsetel ja -nega-
tiivsetel. Keskmine üldine paratsentraalne rakutihedus oli vastavalt 2479 (+422) 
ja 2455 (+475) EXS-positiivsetel ja -negatiivsetel. Esimesel postoperatiivsel 
päeval oli kahe grupi vahel oluline erinevus paratsentraalse endoteliaalse raku-
tiheduse muutuses, vastavalt 8,2% ja 1,1% EXS-positiivsetel ja -negatiivsetel. 
Tsentraalses osas olid gruppidevahelised muutused ühtlasemad. Esimesel post-
operatiivsel päeval oli sedastatav oluline variatsiooni koefitsiendi tõus mõlemas 
grupis, mis viitas lõikuse varasele mõjutusele ja sarvkesta endoteeli ajutisele 
heterogeensusele, ning taandus lõikuseelsele tasemele ühe kuu möödudes. Esi-
mesel lõikusjärgsel päeval oli sarvkesta paksus tõusnud kõigis mõõdetud punk-
tides ja ilma oluliste gruppidevaheliste erinevusteta. Tegu oli samuti vahetu lõi-
kuse mõjuga sarvkestale ning turse taandus lõikuseelsele tasemele ühe kuu 
möödudes mõlemas grupis ilma oluliste gruppidevaheliste erinevusteta. Ühe 
kuu möödudes oli tsentraalse ja paratsentraalse endoteeli rakutiheduse langus 
vastavalt 18,1% ja 12,3% EXS-positiivsetel ja 11,6% ja 6,6% EXS negatiiv-
setel. Rakutiheduse langus oli väljendunum EXS-positiivsetel kuid mitte sta-
tistiliselt oluliselt. Samuti oli kompensatoorselt endoteeli rakkude vähenemisele 
tõusnud endoteeli rakkude pindala kuid jällegi mitte oluliste erinevustega eri 
gruppide vahel. Silma siserõhk oli taandunud lõikuseelsele tasemele mõlemas 
grupis. Regressiooni analüüsil ei omanud ei lõikuse eelsed ega vahetud lõikuse 
järgsed (24h) silma siserõhu näitajad olulist rolli sarvkesta endoteeli rakkude 
muutuses ei EXS-positiivsetel ega -negatiivsetel.  
Operatsiooni kestus oli sarnane mõlemas grupis. Intraoperatiivsetest para-
meetritest oli EXS-positiivsetel oluliselt pikem phaco-aeg ja suurem balanssee-
ritud soolalahuse kulu. Regressioonianalüüsil ei omanud siiski kumbki näita-
jatest eraldivõetuna olulist rolli lõikustulemustele. Küll aga omas olulist toimet 
endoteeli rakkudele phaco-jõud ja seda mõlemas grupis ilma olulise erinevuseta 
eri gruppide vahel. Samuti omas olulist toimet lõikustulemusele summaarne 
phaco: (phaco-jõud korrutatud phaco-ajaga). EXS eraldiseisvana või koos 
phaco-jõuga ei omanud regressiooni analüüsil olulist toimet sarvkesta endotee-
liele, küll aga koos summaarse phaco’ga (r2 = 0,27, p = 0,05). 
 Patsiendid EXS-positiivsete grupis olid oluliselt vanemad kui patsiendid 
EXS-negatiivsete grupis ning regressiooni analüüs näitas olulist negatiivset kor-
relatsiooni kõrgema vanuse ja endoteeli rakkude kahjustuse vahel. Koosmõjus 
eaga ei omanud EXS olulist rolli endoteeli rakkude muutustes. 
 
Järeldused: 
1. Populatsiooniuuring osutas kõrgele (25,5%) EXS esinemissagedusele Eestis 
ja on east sõltuv patoloogia. EXS-i esinemissagedus on samas suurusjärgus 
Soome ja teiste Põhjamaade näitajatega. Regressiooni analüüsil on neil  
1,5-kordne risk katarakti moodustumiseks. 
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2. EXS-positiivsetel on tendents omada kõrgemat silma siserõhku võrreldes 
EXS-negatiivsetega. EXS-positiivsetel esineb oluliselt sagedamini glaukoomi. 
3. EXS-i kõrge esinemissagedus katarakti operatsiooniks saabunuil. Kõrged 
koosesinemise näitajad EXS-i ja katarakti vahel.  
4. Nukleaarne katarakt on levinuim alatüüp EXS-i ja kataratki koos esinemisel. 
5. Kõrgem iga on olulisim riskifaktor sarvkesta endoteeli rakkude kahjustumi-
sel katarakti lõikuse käigus nii EXS-positiivsetel kui -negatiivsetel. Phaco-
jõud on olulisim intraoperatiivne endoteeli rakke kahjustav faktor. EXS eraldi-
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